A Phase 1/2 interventional study of PF-06463922 and Crizotinib in ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC, sponsored by Pfizer. Completed at 77 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-12.
Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 16 under way, 1 of them phase 3. lorlatinib · Carcinoma, Non-Small-Cell Lung.
Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is the only one that started in 2014, is one of 3 in phase 1/2, and was the 1st registered.
7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →8 of the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:
Chugai Pharmaceutical · Sites in United States, Japan
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Pfizer · Sites in France
Ages 18+
Centro di Riferimento Oncologico - Aviano · Sites in Italy
Ages 18+
Guangdong Association of Clinical Trials · Sites in China
Ages 18+
By country, each count listing its studies:
lorlatinib: first FDA approval 2018 (LORBRENA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 1 · Phase 4 3
First in 2014; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 364 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 45 across the 27 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 27 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer: 15 open now, 26 under way, 5 of them phase 3. Of 123 finished, 70 (57%) have results posted.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 20th largest by enrollment of the 136 interventional ones that give a count, is one of 4 that started in 2014, is one of 13 in phase 1/2, and was the 58th registered.
Pfizer’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
1 of the studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07083687Hunan Cancer HospitalLorlatinib in ROS1+ NSCLC With Brain Metastasis | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 158 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .
Inclusion Criteria
Phase 1: ALK-positive NSCLC and ROS1-positive patients must either be treatment naïve in the advanced setting or have had disease progression after at least 1 previous ALK/ROS1 inhibitor therapy(ies).
Phase 2:
ALK-positive NSCLC patients must either be or have had:
ROS1-positive NSCLC patients may be:
Any number of prior therapies (ie, chemotherapy and/or ROS inhibitor therapies).
All Patients must have at least one measurable target extracranial lesion according to v1.1. In addition patients with asymptomatic (including patients asymptomatic by means of stable or decreasing doses of within the last 2 weeks prior to study entry) will be eligible. Patients who have (LM) or carcinomatous meningitis (CM) are eligible.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-06463922
ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.
Drug: Crizotinib
Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
Also known as: Xalkori
Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1
DLT: any of following adverse events (AEs) attributable to PF-06463922: (1) hematologic: grade 4 neutropenia for \>7 days; febrile neutropenia; grade\>=3 neutropenic infection; grade\>=3 thrombocytopenia with bleeding; grade 4 thrombocytopenia; (2) non-hematologic: grade\>=3 pancreatitis; grade\>=3 toxicities (excluding grade \>=3 laboratory abnormalities not requiring dose modifications) persisting after optimal treatment with standard medical therapy; symptomatic grade \>=3 QT interval corrected for heart rate (QTc) prolongation, or asymptomatic grade \>=3 prolongation that had been confirmed by repeat testing, re-evaluation by qualified person, persisted after correction of reversible causes; \>=20% decrease from baseline in left ventricular ejection fraction (LVEF); (3) other: failure to deliver at least 16 out of 21 prescribed daily total dose due to toxicities attributable to study drug; failure to restart dosing after 21 days (1 cycle) delay due to toxicity attributable to study drug.
Time frame: Cycle 1 (21 days)
Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)
Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions electronic case report form (eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.
Time frame: 3 years
Percentage of Participants With Overall and Intracranial Objective Response (Phase 1)
Objective response (OR) refers to confirmed CR or PR according to RECIST version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.
Time frame: From start of study treatment until CR or PR (maximum of 8 years approximately)
Time to Tumor Response (TTR) and Intracranial TTR (Phase 1)
Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. Results presented here were based on independent central review.
Time frame: From start of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 8 years approximately)
Number of Participants With Duration of Response (DOR) and Intracranial DOR (Phase 1)
Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of disease progression (PD) or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.
Time frame: From start of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 8 years approximately)
Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 and 24 Weeks (Phase 1)
Tumor response was evaluated according to RECIST version 1.1, and disease control: confirmed CR, confirmed PR, or stable disease (SD). Intracranial assessment was only performed for participants CNS metastases. CR was defined as disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as 30% or more decrease in SLD of target lesions, taking as reference baseline SLD. Progressive disease: 20% or more increase in SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition to relative increase of 20%, SLD must also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose. Results presented here were based on independent central review.
Time frame: 12 and 24 weeks
Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1)
The probability of the first event being a CNS progression, a non-CNS progression, or death was evaluated with a competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to the analysis set. The time to first event being a Competing Event (either "CNS progression" or "non CNS progression" or "Death") was defined as time from first dose until the date of that specific event. Participants not known to have any of the Competing Events were censored on the date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as a competing cause of failure for the analysis of other type of events. For each type of event, the cumulative incidence function corresponding to the nearest time point preceding 1 year is presented. The results are based on independent central review.
Time frame: 3 years
Progression-Free Survival (PFS) (Phase 1)
PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.
Time frame: From start of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 8 years approximately)
Overall Survival (OS) (Phase 1)
OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.
Time frame: 3 years
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1)
Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 was observed directly from data.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).
Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)
Tmax of PF-06463922 was observed directly from data as time of first occurrence.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Tmax of PF-06463922 was observed directly from data as time of first occurrence.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).
Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)
Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours post-dose on Day -7 for all other groups.
Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1)
AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1)
Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Rac was calculated as Day 15 AUCtau/Day -7 AUCtau or Day 1 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively).
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)
Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Renal Clearance (CLr) of PF-06463922 (Phase 1)
Renal clearance was calculated as Aetau/AUCtau, where Aetau was the cumulative amount of drug recovered unchanged in urine up to dosing interval tau (24 hours for QD dosing regimen), and AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen).
Time frame: 0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15
Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)
Dosing interval was 24 hours for QD dosing regimen. Aetau% was calculated as 100\*Ae24/dose, where Ae24 was the cumulative amount of drug recovered unchanged in urine up to 24 hours post-dose.
Time frame: 0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15
Maximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1)
Cmax of midazolam was observed directly from data. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflected the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflected the PK assessment after multiple doses of PF-06463922 were administered.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Time for Cmax (Tmax) of Midazolam (Phase 1)
Tmax of midazolam was observed directly from data as time of first occurrence. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1)
Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of midazolam was determined using linear/log trapezoidal method. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1)
AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Apparent Oral Clearance (CL/F) of Midazolam (Phase 1)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Apparent Volume of Distribution (Vz/F) of Midazolam (Phase 1)
Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Terminal Half-Life of Midazolam (Phase 1)
Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1)
Plasma circulating nucleic acid (CNA) samples were analyzed for ALK kinase domain mutations by digital polymerase chain reaction (PCR) BEAMing technology. Number of participants with one or more ALK mutations is presented.
Time frame: Screening (up to 28 days)
Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1)
Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.
Time frame: Screening (up to 28 days)
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)
European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
Time frame: From start of study treatment until end of treatment (maximum of 8 years approximately)
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1)
EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
Time frame: From start of study treatment until end of treatment (maximum of 8 years approximately)
Change From Baseline in Mini Mental State Examination (MMSE) Score (Phase 1)
In Phase 1, the MMSE was collected to assess mental status. The MMSE is a 30 item questionnaire that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall and language. The maximum score is 30 and minimum score is 0. Highest score indicates no cognitive impairment, lowest score indicates severe cognitive impairment. The MMSE was removed under Amendment 6 of the study protocol, and not required for Phase 2, as the tool was not considered meaningful for assessment of cognitive function.
Time frame: Baseline, Day 1 of Cycle 1-52, and end of treatment (up to 3 years)
Time to Tumor Response (TTR) and Intracranial TTR (Phase 2 and DDI Sub-study)
Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.
Time frame: From first dose of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Duration of Response (DOR) and Intracranial DOR (Phase 2 and DDI Substudy)
Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of PD or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.
Time frame: From first dose of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Percentage of Participants Achieving Disease Control and Intracranial Disease Control at Week 12 and 24 (Phase 2 and DDI Substudy)
Tumor response was evaluated according to RECIST version 1.1, and disease control was defined as confirmed CR, confirmed PR, or stable disease (SD). CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. SD= when neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD is observed, taking as reference the smallest sum diameters while on study. Intracranial assessment was only performed for participants CNS metastases. Results presented here were based on independent central review.
Time frame: Weeks 12 and 24
Time to Progression on the Last Prior Therapy (Phase 2)
TTP on the last prior therapy was defined as time from the first dose date of the last prior treatment regimen to the date of progression. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose.
Time frame: From first dose of study treatment to the date of progression (maximum of 7.5 years for Phase 2)
Time to Tumor Progression (TTP) and Intracranial TTP (Phase 2 and DDI Substudy)
Time to progression (TTP) was defined as the time from the first dose of study treatment to the first documentation of objective PD. Intracranial TTP was defined as the time from the first dose of study treatment to the date of the first documentation of objective progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.
Time frame: From first dose of study treatment to the first documentation of objective PD (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2)
Probability of first event being CNS progression, non-CNS progression, or death was evaluated with competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to analysis set. Time to first event being Competing Event (either "CNS progression" or "non CNS progression" or "Death") = time from first dose until date of that specific event. Participants not known to have any of Competing Events were censored on date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as competing cause of failure for analysis of other type of events. For each type of event, cumulative incidence function corresponding to nearest time point preceding 1 year is presented. PD:20% or more increase in SLD of target lesion relative to baseline or smallest SLD (nadir) recorded since first dose. SLD must demonstrate absolute increase of atleast 5mm(\>=5 mm) relative to baseline or smallest SLD (nadir) recorded since first dose.
Time frame: From first dose of study treatment until first event of CNS progression (maximum of 7.5 years for Phase 2)
Progression-Free Survival (PFS) (Phase 2 and DDI Substudy)
PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.
Time frame: From first dose of study treatment to first documentation of objective PD or death due to any cause, whichever came first (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Overall Survival (Phase 2 and DDI Substudy)
OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.
Time frame: From first dose of study treatment until date of death (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)
Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Time for Cmax (Tmax) of PF-06463922 (Phase 2)
Tmax of PF-06463922 was observed directly from data as time of first occurrence.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)
AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2)
Tau refers to the dosing interval, and it equals to 24 hours for QD dosing which was adopted in Phase 2. AUCtau was determined using linear/log trapezoidal method.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Apparent Oral Clearance (CL/F) of PF-06463922 (Phase 2)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)
Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
Terminal Half-Life of PF-06463922 (Phase 2)
Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)
Rac was calculated as Day 15 AUCtau/Day -7 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2).
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)
Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2)
Plasma CNA samples were analyzed for ALK kinase domain mutations by Next Generation Sequencing (NGS). Number of participants with one or more ALK mutations is presented.
Time frame: Screening (up to 28 days)
Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2)
Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.
Time frame: Screening (up to 28 days)
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2 and DDI Sub-study)
European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
Time frame: From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2 and DDI Sub-study)
EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
Time frame: From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Number of Participants With Treatment-Emergent Adverse Events (Phase 1, Phase 2 and DDI Sub-study)
AE: any untoward medical occurrence in clinical investigation participant administered a product or medical device, regardless of causal relationship to study treatment. Treatment-emergent AEs (TEAEs): AEs which occurred for first time during effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs): any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of ability to conduction normal life function). AEs included SAEs and non-serious AEs. Severity was graded as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.Grade1: mild, Grade2: moderate, Grade3: severe, Grade4: Life threatening consequences; urgent intervention indicated, Grade 5: death related to AE.
Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Hematology
Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils and absolute basophils. Hematology parameters with any abnormalities were reported in this outcome measure.
Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Chemistry
Chemistry evaluation included alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), blood bilirubin, creatine phosphokinase (CPK), creatinine, gamma-glutamyl transferase (GGT), calcium, sodium, potassium, magnesium, albumin, glucose (non-fasted), albumin, phosphorus or phosphate, serum amylase and lipase.
Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Coagulation, Lipids and Urinalysis
Coagulation evaluation included activated partial thromboplastin time, international normalized ratio (INR), and prothrombin time. Lipid evaluation included Cholesterol and triglycerides.
Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Number of Participants With Vital Signs Data Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)
Blood pressure (BP), including systolic BP (SBP) and diastolic BP (DBP), and pulse rate were recorded in sitting position. Body weight was also measured.
Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1, Phase 2 and DDI Sub-study)
Left Ventricular Ejection Fraction (LVEF) was determined by echocardiogram. Baseline was defined as the measurement prior to the first dose of study treatment.
Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Number of Participants With Absolute Values and Change From Baseline in QTcF Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)
Triplicate 12-lead electrocardiograms (ECGs) were performed approximately 2 minutes apart to determine mean QTc interval (QT interval corrected for heart rate). QT interval was corrected for heart rate using Fridericia's formula to provide QTcF. Absolute values and changes from baseline were summarized according to pre-defined criteria. Baseline was defined as the last evaluation on or prior to the first dose of study treatment.
Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Number of Participants With Suicidal Ideation and Suicidal Behavior (Phase 2)
The Columbia Suicide Severity Rating Scale (C-SSRS) was used to analyze participants' suicidal ideation and behavior, and it is a unique, simple and short method of assessing both behavior and ideation that tracks all suicidal events and provides a summary of suicidality. It assesses the lethality of attempts and other features of ideation (frequency, duration, controllability, reasons for ideation and deterrents), all of which are significantly predictive of completed suicide. Maximum score of 4 or 5 indicates maximum suicidal ideation and minimum score of "0" indicates no suicidal ideation.
Time frame: From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2)
Change From Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2)
The Beck Depression Inventory (BDI)-II is a 21-item self-report scale, with each item rated by participants on a 4-point scale (ranging from 0-3, where 0 indicated lowest depression and 3 indicated severe depression). The scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike, pessimism, and poor concentration) as well as somatic signs (appetite, sleep, fatigue and libido). Scores were obtained by adding up the total points from the series of answers. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.
Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Change From Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2)
The Detection Test is a measure of psychomotor function and uses a well validated simple reaction time paradigm with playing card stimuli. In this test, the on-screen instructions ask: "Has the card turned over?". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as the card flips over the participant must press "Yes". The participant is encouraged to work as quickly as they can and be as accurate as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Change From Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2)
The Identification Test is a measure of visual attention and uses a well validated choice reaction time paradigm with playing card stimuli. In this task, the playing cards are all red or black jokers. The on-screen instructions ask: "Is the card red?". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as it flips over the participant must decide whether the card is red or not. If it is red the participant should press "Yes", and if it is not red the participant should press "No". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Change From Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2)
The One Back Test is a measure of working memory and uses a well validated n back paradigm with playing cards. In this task, the on-screen instructions ask: "Is the previous card the same?". A playing card is presented in the center of the screen. The participant must decide whether the card is the same as the previous card. If it is the same the participant should press "Yes", and if not press "No". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded, mean of the log10 transformed reaction times for correct responses is used to demonstrate speed of performance, and the arcsine transformation of the square root of the proportion of correct responses is used to demonstrate accuracy. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Change From Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2)
The International Shopping List task is a measure of verbal learning and uses a well validated list learning paradigm administered using a computer. High frequencies, high imagery, concrete nouns (items from a shopping list) were read to the participant at the rate of one word every 2 seconds. Once all 12 words had been read, the participant was asked to recall as many of the words as quickly as possible. The words recalled by the participant were marked on the computer screen. When the participant could recall no more words, the same list was read again. The words recalled by the participant were recorded. This was then repeated a third time. Total number of correct responses on 3 consecutive trials at a single assessment was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Change From Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2)
This test was performed in the same way as the International Shopping List Test, with the exception that, the delayed recall condition required the participant to recall the words from the list 15 30 minutes later without having the list read again. During the recognition condition, the qualified personnel read a shopping list item that may or may not have been on the original list and the participant had to respond either affirmatively (if the item was on the original list) or negatively (if it was not). Total number of correct responses made in remembering the word list after a delay was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Number of Participants With Absolute Values and Change From Baseline in PR Interval Meeting Pre-defined Criteria (Phase 2 and DDI Substudy)
PR Interval was determined by ECG measurement. PR interval had following categories: change from baseline\>=25 percent, 40 to \<60 milliseconds (msec), 60 to \<80 msec and \>=80 msec. Baseline was defined as the average of the triplicate measurements prior to the first dose of study drug.
Time frame: From first dose of study treatment to end of treatment maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Percentage of Participants With Overall and Intracranial Objective Response (Phase 2 and DDI Sub-study)
Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.
Time frame: From first dose of study treatment to end of treatment maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
| Milestone | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | Japan Lead-In Cohort (LIC) | Drug-drug Interaction (DDI) Sub-study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 12 | 17 | 3 | 3 | 3 | 3 | 4 | 30 | 27 | 60 | 65 | 46 | 47 | 3 | 32 |
| Completed | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 1 | 2 | 18 | 7 | 18 | 8 | 3 | 7 | 2 | 6 |
| Not completed | 3 | 3 | 3 | 10 | 14 | 3 | 3 | 3 | 2 | 2 | 12 | 20 | 42 | 57 | 43 | 40 | 1 | 26 |
| Withdrew: Death | 3 | 2 | 3 | 6 | 9 | 3 | 2 | 3 | 2 | 2 | 8 | 13 | 25 | 46 | 37 | 22 | 1 | 17 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 4 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 3 | 8 | 3 | 2 | 3 | 0 | 2 |
| Withdrew: Participant refused further follow-up | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 7 | 8 | 3 | 11 | 0 | 6 |
DLT: any of following adverse events (AEs) attributable to PF-06463922: (1) hematologic: grade 4 neutropenia for \>7 days; febrile neutropenia; grade\>=3 neutropenic infection; grade\>=3 thrombocytopenia with bleeding; grade 4 thrombocytopenia; (2) non-hematologic: grade\>=3 pancreatitis; grade\>=3 toxicities (excluding grade \>=3 laboratory abnormalities not requiring dose modifications) persisting after optimal treatment with standard medical therapy; symptomatic grade \>=3 QT interval corrected for heart rate (QTc) prolongation, or asymptomatic grade \>=3 prolongation that had been confirmed by repeat testing, re-evaluation by qualified person, persisted after correction of reversible causes; \>=20% decrease from baseline in left ventricular ejection fraction (LVEF); (3) other: failure to deliver at least 16 out of 21 prescribed daily total dose due to toxicities attributable to study drug; failure to restart dosing after 21 days (1 cycle) delay due to toxicity attributable to study drug.
| Participants | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| With DLT | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| No DLT | 3 | 2 | 3 | 6 | 8 | 2 | 1 | 2 | 3 | 2 |
| Data missing | 0 | 1 | 0 | 5 | 8 | 1 | 1 | 0 | 0 | 1 |
Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions electronic case report form (eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.
| Percentage of participants | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) |
|---|---|---|---|---|---|---|
| Objective response | 90.0 (73.5 to 97.9) | 74.1 (53.7 to 88.9) | 50.8 (37.5 to 64.1) | 41.5 (29.4 to 54.4) | 34.8 (21.4 to 50.2) | 36.2 (22.7 to 51.5) |
| Intracranial objective response | 75.0 (34.9 to 96.8) | 58.8 (32.9 to 81.6) | 62.5 (43.7 to 78.9) | 55.6 (40.0 to 70.4) | 39.5 (24.0 to 56.6) | 56.0 (34.9 to 75.6) |
Objective response (OR) refers to confirmed CR or PR according to RECIST version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.
| Percentage of participants | ALK Positive Population (Phase 1) | ROS1 Positive Population (Phase 1) |
|---|---|---|
| Objective response | 39.0 (24.2 to 55.5) | 50.0 (21.1 to 78.9) |
| Intracranial objective response | 41.2 (24.6 to 59.3) | 50.0 (15.7 to 84.3) |
Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. Results presented here were based on independent central review.
| Months | ALK Positive Population (Phase 1) | ROS1 Positive Population (Phase 1) |
|---|---|---|
| TTR | 1.4 (1.2 to 15.2) | 1.4 (1.2 to 2.8) |
| Intracranial TTR | 1.4 (1.2 to 20.1) | 1.4 (1.1 to 2.8) |
Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of disease progression (PD) or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.
| Participants | ALK Positive Population (Phase 1) | ROS1 Positive Population (Phase 1) |
|---|---|---|
| Participants with DOR — <3 Months | 1 | 0 |
| Participants with DOR — 3 Months to <6 Months | 6 | 0 |
| Participants with DOR — 6 Months to <9 Months | 0 | 1 |
| Participants with DOR — 9 Months to <12 Months | 0 | 1 |
| Participants with DOR — 12 Months to <15 Months | 1 | 0 |
| Participants with DOR — 15 Months to <18 Months | 0 | 0 |
| Participants with DOR — 18 Months to <21 Months | 0 | 0 |
| Participants with DOR — 21 Months to <24 Months | 1 | 0 |
| Participants with DOR — >=24 Months | 1 | 2 |
| Participants censored-DOR — <3 Months | 0 | 0 |
| Participants censored-DOR — 3 Months to <6 Months | 0 | 0 |
| Participants censored-DOR — 6 Months to <9 Months | 0 | 0 |
| Participants censored-DOR — 9 Months to <12 Months | 0 | 0 |
| Participants censored-DOR — 12 Months to <15 Months | 0 | 0 |
| Participants censored-DOR — 15 Months to <18 Months | 0 | 0 |
| Participants censored-DOR — 18 Months to <21 Months | 0 | 0 |
| Participants censored-DOR — 21 Months to <24 Months | 0 | 1 |
| Participants censored-DOR — >=24 Months | 6 | 1 |
| Participants with intracranial DOR — <3 Months | 1 | 0 |
| Participants with intracranial DOR — 3 Months to <6 Months | 0 | 0 |
| Participants with intracranial DOR — 6 Months to <9 Months | 1 | 0 |
| Participants with intracranial DOR — 9 Months to <12 Months | 0 | 0 |
| Participants with intracranial DOR — 12 Months to <15 Months | 1 | 0 |
| Participants with intracranial DOR — 15 Months to <18 Months | 0 | 0 |
| Participants with intracranial DOR — 18 Months to <21 Months | 0 | 0 |
| Participants with intracranial DOR — 21 Months to <24 Months | 0 | 0 |
| Participants with intracranial DOR — >=24 Months | 0 | 0 |
| Participants censored- intracranial DOR — <3 Months | 1 | 1 |
| Participants censored- intracranial DOR — 3 Months to <6 Months | 2 | 0 |
| Participants censored- intracranial DOR — 6 Months to <9 Months | 0 | 0 |
| Participants censored- intracranial DOR — 9 Months to <12 Months | 0 | 0 |
| Participants censored- intracranial DOR — 12 Months to <15 Months | 1 | 0 |
| Participants censored- intracranial DOR — 15 Months to <18 Months | 0 | 0 |
| Participants censored- intracranial DOR — 18 Months to <21 Months | 1 | 2 |
| Participants censored- intracranial DOR — 21 Months to <24 Months | 0 | 0 |
| Participants censored- intracranial DOR — >=24 Months | 6 | 1 |
Tumor response was evaluated according to RECIST version 1.1, and disease control: confirmed CR, confirmed PR, or stable disease (SD). Intracranial assessment was only performed for participants CNS metastases. CR was defined as disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as 30% or more decrease in SLD of target lesions, taking as reference baseline SLD. Progressive disease: 20% or more increase in SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition to relative increase of 20%, SLD must also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose. Results presented here were based on independent central review.
| Percentage of participants | ALK Positive Population (Phase 1) | ROS1 Positive Population (Phase 1) |
|---|---|---|
| DCR at Week 12 | 53.7 (37.4 to 69.3) | 58.3 (27.7 to 84.8) |
| DCR at Week 24 | 39.0 (24.2 to 55.5) | 50.0 (21.1 to 78.9) |
| Intracranial DCR at Week 12 | 50.0 (32.4 to 67.6) | 37.5 (8.5 to 75.5) |
| Intracranial DCR at Week 24 | 41.2 (24.6 to 59.3) | 37.5 (8.5 to 75.5) |
The probability of the first event being a CNS progression, a non-CNS progression, or death was evaluated with a competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to the analysis set. The time to first event being a Competing Event (either "CNS progression" or "non CNS progression" or "Death") was defined as time from first dose until the date of that specific event. Participants not known to have any of the Competing Events were censored on the date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as a competing cause of failure for the analysis of other type of events. For each type of event, the cumulative incidence function corresponding to the nearest time point preceding 1 year is presented. The results are based on independent central review.
| Probability of events | Phase 1 ITT Population |
|---|---|
| CNS progression | 0.260 |
| Non CNS progression | 0.352 |
| Death | 0.060 |
PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.
| Months | ALK Positive Population (Phase 1) | ROS1 Positive Population (Phase 1) |
|---|---|---|
| Progression-Free Survival (PFS) (Phase 1) | 5.4 (2.7 to 11.8) | 10.1 (1.6 to 33.0) |
OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.
| Months | ALK Positive Population (Phase 1) | ROS1 Positive Population (Phase 1) |
|---|---|---|
| Overall Survival (OS) (Phase 1) | 22.3 (11.4 to NA) | NA (4.7 to NA) |
Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.
| Nanograms per milliliter (ng/mL) | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1) | 50.80 ± 17 | 149.2 ± 71 | NA ± NA | 489.1 ± 45 | 595.5 ± 37 | 760.0 ± 58 | 1201 ± 19 | 202.2 ± 57 | 594.9 ± 27 | 507.2 ± 51 |
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 was observed directly from data.
| ng/mL | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1) | 67.29 ± 18 | 138.1 ± 35 | 359.7 ± 27 | 429.6 ± 48 | 550.2 ± 32 | 541.0 ± 42 | NA ± NA | NA ± NA | 550.0 ± 23 | 600.5 ± 27 |
Tmax of PF-06463922 was observed directly from data as time of first occurrence.
| Hours | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1) | 1.98 (1.00 to 2.97) | 2.00 (0.50 to 2.05) | 1.25 (0.50 to 2.00) | 1.09 (0.50 to 4.03) | 1.96 (0.517 to 4.33) | 1.05 (1.00 to 3.00) | 2.00 (1.18 to 3.00) | 1.20 (0.50 to 1.97) | 1.23 (1.00 to 2.00) | 2.00 (1.10 to 3.07) |
Tmax of PF-06463922 was observed directly from data as time of first occurrence.
| Hours | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1) | 1.00 (1.00 to 1.08) | 1.00 (1.00 to 2.00) | 2.00 (1.92 to 2.75) | 1.03 (0.50 to 2.00) | 1.13 (1.00 to 4.00) | 1.30 (1.00 to 24.0) | 1.61 (1.22 to 2.00) | 0.50 (0.50 to 0.50) | 0.55 (0.50 to 2.05) | 2.00 (1.00 to 2.00) |
Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.
| Nanogram*hour/milliliter (ng*hr/mL) | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1) | 488.2 ± 21 | 1387 ± 35 | NA ± NA | 3990 ± 55 | 5110 ± 28 | 7474 ± 73 | 11410 ± 43 | 982.4 ± 9 | 2996 ± 20 | 2925 ± 47 |
Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.
| ng*hr/mL | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1) | 752.1 ± 26 | 1701 ± 29 | 3367 ± 39 | 4107 ± 53 | 5121 ± 30 | 6157 ± 9 | NA ± NA | NA ± NA | 3574 ± 35 | 4058 ± 33 |
AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.
| ng*hr/mL | 10 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1) | NA ± NA | NA ± NA | 7663 ± 79 | 8236 ± 25 | 18340 ± 61 | NA ± NA | NA ± NA | 6318 ± 56 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
| Liter/hour (L/hr) | 10 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|
| Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1) | NA ± NA | NA ± NA | 9.788 ± 79 | 12.14 ± 25 | 10.90 ± 61 | NA ± NA | NA ± NA | 15.83 ± 56 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
| L/hr | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1) | 13.27 ± 26 | 14.72 ± 29 | 14.84 ± 39 | 17.66 ± 48 | 19.52 ± 30 | 24.37 ± 9 | NA ± NA | NA ± NA | 20.99 ± 35 | 22.37 ± 47 |
Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.
| Liters (L) | 10 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1) | NA ± NA | NA ± NA | 367.9 ± 54 | 356.3 ± 39 | 307.8 ± 41 | NA ± NA | NA ± NA | 378.3 ± 54 |
Rac was calculated as Day 15 AUCtau/Day -7 AUCtau or Day 1 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively).
| Ratio | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1) | 1.543 ± 0.075056 | 1.237 ± 0.20817 | 1.105 ± NA | 1.121 ± 0.44575 | 1.071 ± 0.31138 | 1.000 ± 0.79137 | 0.6500 ± NA | NA ± NA | 1.231 ± 0.35228 | 1.523 ± 0.29569 |
Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.
| Hours (hr) | 10 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|
| Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1) | NA ± NA | 23.70 ± NA | 27.22 ± 8.2961 | 20.89 ± 5.0308 | 19.80 ± 3.3045 | 25.55 ± NA | NA ± NA | 17.18 ± 5.1874 |
Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
| Ratio | 10 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|
| Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1) | NA ± NA | 0.5600 ± NA | 0.6131 ± 0.29021 | 0.6603 ± 0.18604 | 0.3935 ± NA | NA ± NA | NA ± NA | 0.7687 ± 0.13552 |
Renal clearance was calculated as Aetau/AUCtau, where Aetau was the cumulative amount of drug recovered unchanged in urine up to dosing interval tau (24 hours for QD dosing regimen), and AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen).
| ml/hour | 100 mg QD (Phase 1) |
|---|---|
| Renal Clearance (CLr) of PF-06463922 (Phase 1) | 61.31 ± 58 |
Dosing interval was 24 hours for QD dosing regimen. Aetau% was calculated as 100\*Ae24/dose, where Ae24 was the cumulative amount of drug recovered unchanged in urine up to 24 hours post-dose.
| Percentage of recovered PF-06463922 | 100 mg QD (Phase 1) |
|---|---|
| Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1) | 0.4017 ± 0.11074 |
Cmax of midazolam was observed directly from data. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflected the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflected the PK assessment after multiple doses of PF-06463922 were administered.
| ng/mL | 25 mg QD (Phase 1) | 150 mg QD (Phase 1) |
|---|---|---|
| Day -7 | 16.06 ± 42 | 11.56 ± 48 |
| Cycle 1 Day 15 | 9.697 ± 40 | 5.734 ± 43 |
Tmax of midazolam was observed directly from data as time of first occurrence. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
| Hours | 25 mg QD (Phase 1) | 150 mg QD (Phase 1) |
|---|---|---|
| Day -7 | 0.50 (0.50 to 1.00) | 0.50 (0.50 to 0.50) |
| Cycle 1 Day 15 | 0.50 (0.50 to 1.00) | 0.50 (0.50 to 0.533) |
Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of midazolam was determined using linear/log trapezoidal method. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
| ng*hr/mL | 25 mg QD (Phase 1) | 150 mg QD (Phase 1) |
|---|---|---|
| Day -7 | 51.30 ± 47 | 36.49 ± 20 |
| Cycle 1 Day 15 | 20.43 ± 18 | 14.44 ± 25 |
AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
| ng*hr/mL | 25 mg QD (Phase 1) | 150 mg QD (Phase 1) |
|---|---|---|
| Day -7 | 54.53 ± 43 | NA ± NA |
| Cycle 1 Day 15 | 21.32 ± 18 | 16.09 ± 29 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
| L/hr | 25 mg QD (Phase 1) | 150 mg QD (Phase 1) |
|---|---|---|
| Day -7 | 36.68 ± 43 | NA ± NA |
| Cycle 1 Day 15 | 93.86 ± 18 | 124.2 ± 29 |
Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
| Liters | 25 mg QD (Phase 1) | 150 mg QD (Phase 1) |
|---|---|---|
| Day -7 | 229.0 ± 7 | NA ± NA |
| Cycle 1 Day 15 | 404.4 ± 51 | 702.2 ± 100 |
Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
| Hours | 25 mg QD (Phase 1) | 150 mg QD (Phase 1) |
|---|---|---|
| Day -7 | 4.620 ± 1.9328 | 5.120 ± NA |
| Cycle 1 Day 15 | 3.343 ± 2.0358 | 5.257 ± 5.0639 |
Plasma circulating nucleic acid (CNA) samples were analyzed for ALK kinase domain mutations by digital polymerase chain reaction (PCR) BEAMing technology. Number of participants with one or more ALK mutations is presented.
| Participants | ALK Positive Population (Phase 1) |
|---|---|
| Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1) | 14 |
Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.
| Participants | ALK Positive Population (Phase 1) |
|---|---|
| Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1) | 7 |
European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
| Participants | Phase 1 PRO Evaluable Population |
|---|---|
| Improved in global QoL | 19 |
| Stable in global QoL | 13 |
| Worsened in global QoL | 11 |
| Improved in physical functioning | 5 |
| Stable in physical functioning | 29 |
| Worsened in physical functioning | 9 |
| Improved in role functioning | 14 |
| Stable in role functioning | 15 |
| Worsened in role functioning | 14 |
| Improved in emotional functioning | 15 |
| Stable in emotional functioning | 21 |
| Worsened in emotional functioning | 7 |
| Improved in cognitive functioning | 8 |
| Stable in cognitive functioning | 21 |
| Worsened in cognitive functioning | 14 |
| Improved in social functioning | 13 |
| Stable in social functioning | 17 |
| Worsened in social functioning | 13 |
| Improved in fatigue | 17 |
| Stable in fatigue | 19 |
| Worsened in fatigue | 7 |
| Improved in nausea and vomiting | 10 |
| Stable in nausea and vomiting | 32 |
| worsened in nausea and vomiting | 1 |
| Improved in pain | 17 |
| Stable in pain | 16 |
| Worsened in pain | 10 |
| Improved in dyspnea | 13 |
| Stable in dyspnea | 19 |
| Worsened in dyspnea | 11 |
| Improved in insomnia | 19 |
| Stable in insomnia | 17 |
| Worsened in insomnia | 7 |
| Improved in appetite loss | 14 |
| Stable in appetite loss | 27 |
| Worsened in appetite loss | 2 |
| Improved in constipation | 10 |
| Stable in constipation | 28 |
| Worsened in constipation | 5 |
| Improved in diarrhea | 9 |
| Stable in diarrhea | 28 |
| Worsened in diarrhea | 6 |
| Improved in financial difficulties | 7 |
| Stable in financial difficulties | 20 |
| Worsened in financial difficulties | 16 |
EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
| Participants | Phase 1 PRO Evaluable Population |
|---|---|
| Improved in dyspnea | 9 |
| Stable in dyspnea | 23 |
| Worsened in dyspnea | 11 |
| Improved in coughing | 23 |
| Stable in coughing | 12 |
| Worsened in coughing | 8 |
| Improved in hemoptysis | 1 |
| Stable in hemoptysis | 42 |
| Worsened in hemoptysis | 0 |
| Improved in sore mouth | 0 |
| Stable in sore mouth | 40 |
| Worsened in sore mouth | 3 |
| Improved in dysphagia | 4 |
| Stable in dysphagia | 37 |
| Worsened in dysphagia | 2 |
| Improved in peripheral neuropathy | 6 |
| Stable in peripheral neuropathy | 21 |
| Worsened in peripheral neuropathy | 16 |
| Improved in alopecia | 4 |
| Stable in alopecia | 29 |
| Worsened in alopecia | 9 |
| Improved in chest pain | 16 |
| Stable in chest pain | 22 |
| Worsened in chest pain | 5 |
| Improved in arm or shoulder pain | 10 |
| Stable in arm or shoulder pain | 27 |
| Worsened in arm or shoulder pain | 6 |
| Improved in pain in other parts | 20 |
| Stable in pain in other parts | 12 |
| Worsened in pain in other parts | 11 |
In Phase 1, the MMSE was collected to assess mental status. The MMSE is a 30 item questionnaire that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall and language. The maximum score is 30 and minimum score is 0. Highest score indicates no cognitive impairment, lowest score indicates severe cognitive impairment. The MMSE was removed under Amendment 6 of the study protocol, and not required for Phase 2, as the tool was not considered meaningful for assessment of cognitive function.
| Units on a scale | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 1.0 ± 1.41 | — | -0.5 ± 0.71 | -0.9 ± 2.27 | 0.8 ± 1.39 | — | — | — | 0.0 ± NA | 0.0 ± NA |
| Cycle 2 Day 1 | 2.0 ± NA | -0.3 ± 0.58 | 2.0 ± NA | 0.3 ± 1.41 | 0.0 ± 1.79 | 4.7 ± 8.08 | 4.0 ± 4.24 | 0.0 ± 0.00 | 0.0 ± 0.00 | -0.3 ± 1.15 |
| Cycle 3 Day 1 | 2.0 ± 0.00 | 0.3 ± 0.58 | -0.5 ± 0.71 | -0.6 ± 1.85 | 0.2 ± 1.52 | 5.0 ± 8.49 | 3.0 ± 2.83 | — | 0.0 ± NA | -1.0 ± 1.00 |
| Cycle 4 Day 1 | 5.0 ± NA | 0.5 ± 0.71 | 1.5 ± 2.12 | -1.1 ± 1.81 | 0.0 ± 1.47 | 2.0 ± 6.24 | -0.5 ± 3.54 | — | 0.0 ± NA | -0.7 ± 1.15 |
| Cycle 5 Day 1 | 0.5 ± 3.54 | 0.5 ± 0.71 | 1.5 ± 2.12 | 0.3 ± 1.25 | -0.2 ± 1.72 | 4.7 ± 8.14 | 0.5 ± 6.36 | — | 0.0 ± NA | -0.5 ± 0.71 |
| Cycle 6 Day 1 | 2.5 ± 2.12 | 0.5 ± 0.71 | 1.0 ± 1.41 | -0.4 ± 2.70 | 0.3 ± 0.90 | 4.3 ± 5.86 | 2.0 ± 4.24 | — | 0.0 ± NA | -1.3 ± 2.31 |
| Cycle 7 Day 1 | 2.0 ± NA | 0.5 ± 0.71 | 1.5 ± 2.12 | -0.1 ± 1.21 | 0.4 ± 0.90 | 4.7 ± 8.33 | 3.0 ± 4.24 | — | 0.0 ± NA | -0.7 ± 1.15 |
| Cycle 8 Day 1 | -4.0 ± NA | 0.5 ± 0.71 | 1.5 ± 2.12 | -0.1 ± 2.34 | 0.2 ± 1.34 | 3.0 ± 7.81 | 4.0 ± 4.24 | — | 0.0 ± NA | 0.0 ± 0.00 |
| Cycle 9 Day 1 | — | 0.0 ± 0.00 | 0.0 ± NA | -1.0 ± 2.31 | 0.3 ± 2.10 | 6.0 ± 8.49 | 6.0 ± NA | — | — | -0.3 ± 0.58 |
| Cycle 10 Day 1 | -5.0 ± NA | 0.5 ± 0.71 | 0.0 ± NA | 0.0 ± 0.00 | -0.1 ± 0.88 | 6.5 ± 9.19 | 6.0 ± NA | — | 0.0 ± NA | -1.7 ± 1.53 |
| Cycle 11 Day 1 | — | -0.5 ± 0.71 | 0.0 ± NA | 0.3 ± 1.70 | -0.2 ± 1.53 | 7.0 ± 8.49 | 3.5 ± 3.54 | — | 0.0 ± NA | 0.0 ± 0.00 |
| Cycle 12 Day 1 | — | 0.5 ± 0.71 | — | -0.6 ± 2.19 | -0.2 ± 2.33 | 6.5 ± 9.19 | 3.5 ± 3.54 | — | 0.0 ± NA | -0.7 ± 0.58 |
| Cycle 13 Day 1 | — | 0.5 ± 0.71 | — | 0.8 ± 1.79 | 0.5 ± 2.22 | 5.5 ± 7.78 | 3.0 ± 4.24 | — | 0.0 ± NA | -0.5 ± 0.71 |
| Cycle 14 Day 1 | — | 0.5 ± 0.71 | — | -0.3 ± 3.20 | 0.3 ± 0.79 | 6.0 ± 8.49 | 2.5 ± 3.54 | — | 0.0 ± NA | 0.0 ± 0.00 |
| Cycle 15 Day 1 | — | 0.5 ± 0.71 | — | -1.7 ± 5.43 | 0.1 ± 1.36 | — | 4.0 ± 4.24 | — | 0.0 ± NA | -0.3 ± 0.58 |
| Cycle 16 Day 1 | — | 0.0 ± 1.41 | — | -0.2 ± 2.49 | -0.2 ± 1.99 | 1.0 ± NA | 1.5 ± 6.36 | — | 0.0 ± NA | 0.0 ± 0.00 |
| Cycle 17 Day 1 | — | -2.0 ± 2.83 | — | 0.6 ± 1.95 | 0.1 ± 1.17 | -3.0 ± NA | 4.0 ± 4.24 | — | 0.0 ± NA | -1.3 ± 1.53 |
| Cycle 18 Day 1 | — | -0.5 ± 0.71 | — | 0.8 ± 1.79 | 0.0 ± 1.73 | -2.0 ± NA | 3.0 ± 4.24 | — | — | 0.0 ± 0.00 |
| Cycle 19 Day 1 | — | -0.5 ± 0.71 | — | 0.8 ± 1.79 | -0.6 ± 2.65 | 0.0 ± NA | 3.5 ± 4.95 | — | 0.0 ± NA | -0.5 ± 0.71 |
| Cycle 20 Day 1 | — | 0.0 ± 0.00 | — | 0.0 ± 1.41 | 0.7 ± 2.12 | 0.0 ± NA | 3.5 ± 3.54 | — | 0.0 ± NA | -0.5 ± 0.71 |
| Cycle 21 Day 1 | — | -0.5 ± 0.71 | — | 0.0 ± 1.41 | 0.1 ± 2.09 | — | 4.0 ± 4.24 | — | 0.0 ± NA | -0.5 ± 0.71 |
| Cycle 22 Day 1 | — | 0.0 ± 0.00 | — | 0.4 ± 1.52 | 0.1 ± 1.45 | 0.0 ± NA | 3.5 ± 3.54 | — | -1.0 ± NA | -0.3 ± 0.58 |
| Cycle 23 Day 1 | — | 0.5 ± 0.71 | — | 0.0 ± 1.41 | 0.1 ± 1.81 | -1.0 ± NA | 1.5 ± 3.54 | — | 0.0 ± NA | -2.3 ± 4.04 |
| Cycle 24 Day 1 | — | 0.5 ± 0.71 | — | -0.4 ± 0.89 | 0.6 ± 0.74 | 1.0 ± NA | 1.5 ± 4.95 | — | 0.0 ± NA | 0.0 ± 0.00 |
| Cycle 25 Day 1 | — | 0.0 ± 0.00 | — | 0.8 ± 1.79 | -0.9 ± 2.27 | -2.0 ± NA | 2.5 ± 4.95 | — | 0.0 ± NA | 0.0 ± 0.00 |
| Cycle 26 Day 1 | — | 0.5 ± 0.71 | — | 0.8 ± 1.79 | -0.4 ± 2.77 | -1.0 ± NA | 2.0 ± 4.24 | — | 0.0 ± NA | -0.3 ± 0.58 |
| Cycle 27 Day 1 | — | 0.5 ± 0.71 | — | 0.8 ± 1.79 | -0.1 ± 2.67 | -1.0 ± NA | 3.5 ± 3.54 | — | 0.0 ± NA | -1.0 ± 1.41 |
| Cycle 28 Day 1 | — | 0.5 ± 0.71 | — | 1.0 ± 2.00 | 0.7 ± 0.76 | -2.0 ± NA | 3.0 ± 2.83 | — | 0.0 ± NA | 0.0 ± 0.00 |
| Cycle 29 Day 1 | — | -1.5 ± 2.12 | — | 0.5 ± 1.73 | 0.1 ± 1.81 | 0.0 ± NA | 3.5 ± 3.54 | — | 0.0 ± NA | 0.0 ± 0.00 |
| Cycle 30 Day 1 | — | 0.0 ± 0.00 | — | 0.8 ± 1.50 | 0.4 ± 0.55 | 0.0 ± NA | 3.0 ± 2.83 | — | 0.0 ± NA | -1.0 ± 1.00 |
| Cycle 31 Day 1 | — | 0.5 ± 0.71 | — | 1.0 ± 2.65 | 0.7 ± 0.82 | 0.0 ± NA | 3.0 ± 4.24 | — | — | 0.0 ± 0.00 |
| Cycle 32 Day 1 | — | 0.0 ± 0.00 | — | 1.3 ± 2.31 | 0.4 ± 0.55 | — | 3.5 ± 3.54 | — | 0.0 ± NA | 0.0 ± 0.00 |
| Cycle 33 Day 1 | — | 0.0 ± 0.00 | — | 1.3 ± 2.31 | 0.5 ± 0.58 | — | 3.5 ± 3.54 | — | 0.0 ± NA | 0.0 ± 0.00 |
| Cycle 34 Day 1 | — | 0.0 ± 0.00 | — | 0.0 ± 0.00 | 0.3 ± 0.50 | — | 4.0 ± 4.24 | — | 0.0 ± NA | 0.0 ± 0.00 |
| Cycle 35 Day 1 | — | 0.5 ± 0.71 | — | 0.0 ± NA | 0.3 ± 0.50 | — | 4.0 ± 4.24 | — | 0.0 ± NA | 0.0 ± NA |
| Cycle 36 Day 1 | — | -0.5 ± 0.71 | — | 0.0 ± NA | 0.0 ± 0.00 | — | 4.0 ± 4.24 | — | 0.0 ± NA | 0.0 ± NA |
| Cycle 37 Day 1 | — | 0.0 ± 0.00 | — | -1.0 ± NA | 0.0 ± 0.00 | — | 3.5 ± 4.95 | — | — | — |
| Cycle 38 Day 1 | — | 0.0 ± 0.00 | — | 0.0 ± NA | 0.0 ± 0.00 | — | 3.0 ± 2.83 | — | 0.0 ± NA | — |
| Cycle 39 Day 1 | — | 0.0 ± NA | — | 0.0 ± NA | -0.5 ± 0.71 | — | 3.5 ± 4.95 | — | — | — |
| Cycle 40 Day 1 | — | 0.5 ± 0.71 | — | -1.0 ± NA | 0.0 ± NA | — | 4.0 ± 4.24 | — | — | — |
| Cycle 41 Day 1 | — | 0.5 ± 0.71 | — | 0.0 ± NA | 0.0 ± NA | — | 1.5 ± 6.36 | — | — | — |
| Cycle 42 Day 1 | — | -0.5 ± 0.71 | — | 0.0 ± NA | 0.0 ± NA | — | 4.0 ± 4.24 | — | — | — |
| Cycle 43 Day 1 | — | 0.0 ± 0.00 | — | 0.0 ± NA | — | — | 4.0 ± 4.24 | — | — | — |
| Cycle 44 Day 1 | — | 1.0 ± NA | — | -1.0 ± NA | — | — | 3.0 ± 4.24 | — | — | — |
| Cycle 45 Day 1 | — | 1.0 ± NA | — | 0.0 ± NA | — | — | 1.0 ± NA | — | — | — |
| Cycle 46 Day 1 | — | 0.0 ± NA | — | -1.0 ± NA | — | — | — | — | — | — |
| Cycle 47 Day 1 | — | 0.0 ± NA | — | 0.0 ± NA | — | — | — | — | — | — |
| Cycle 48 Day 1 | — | -3.0 ± NA | — | 0.0 ± NA | — | — | — | — | — | — |
| Cycle 49 Day 1 | — | 0.5 ± 0.71 | — | — | — | — | — | — | — | — |
| Cycle 50 Day 1 | — | -3.0 ± NA | — | — | — | — | — | — | — | — |
| Cycle 51 Day 1 | — | -0.5 ± 0.71 | — | — | — | — | — | — | — | — |
| Cycle 52 Day 1 | — | 1.0 ± NA | — | — | — | — | — | — | — | — |
| End of treatment | -8.0 ± NA | — | 0.7 ± 1.15 | -2.0 ± NA | -2.3 ± 5.19 | — | — | — | -15.0 ± NA | 0.0 ± NA |
Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.
| Months | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|
| TTR | 1.4 (1.2 to 5.4) | 1.4 (1.2 to 18.0) | 1.4 (1.1 to 16.6) | 2.6 (1.2 to 16.4) | 1.4 (1.2 to 9.3) | 1.4 (1.3 to 29.7) | 1.4 (1.2 to 11.0) |
| Intracranial TTR | 2.1 (1.2 to 2.8) | 1.4 (1.2 to 1.5) | 1.4 (1.1 to 5.7) | 1.7 (1.2 to 17.5) | 1.4 (1.2 to 10.6) | 1.4 (1.2 to 28.9) | 2.0 (1.1 to 4.2) |
Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of PD or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.
| Months | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|
| DOR | 17.16 (12.45 to 35.09) | 16.56 (4.20 to NA) | 11.10 (5.55 to NA) | 15.08 (5.55 to 26.28) | 7.03 (4.17 to 11.01) | 19.61 (11.10 to NA) | 5.19 (4.17 to NA) |
| Intra-cranial DOR | NA (8.28 to NA) | NA (20.99 to NA) | 37.12 (8.38 to NA) | 14.52 (11.07 to NA) | 10.32 (6.90 to 14.98) | 17.62 (4.99 to NA) | NA (2.76 to NA) |
Tumor response was evaluated according to RECIST version 1.1, and disease control was defined as confirmed CR, confirmed PR, or stable disease (SD). CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. SD= when neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD is observed, taking as reference the smallest sum diameters while on study. Intracranial assessment was only performed for participants CNS metastases. Results presented here were based on independent central review.
| Percentage of participants | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|
| Disease control rate at Week 12 | 93.3 (77.9 to 99.2) | 85.2 (66.3 to 95.8) | 68.3 (55.0 to 79.7) | 64.6 (51.8 to 76.1) | 50.0 (34.9 to 65.1) | 66.0 (50.7 to 79.1) | 56.3 (37.7 to 73.6) |
| Disease control rate at Week 24 | 83.3 (65.3 to 94.4) | 63.0 (42.4 to 80.6) | 51.7 (38.4 to 64.8) | 49.2 (36.6 to 61.9) | 32.6 (19.5 to 48.0) | 48.9 (34.1 to 63.9) | 34.4 (18.6 to 53.2) |
| Intra-cranial disease control rate at Week 12 | 87.5 (47.3 to 99.7) | 94.1 (71.3 to 99.9) | 75.8 (57.7 to 88.9) | 75.6 (60.5 to 87.1) | 67.6 (50.2 to 82.0) | 72.0 (50.6 to 87.9) | 56.3 (29.9 to 80.2) |
| Intra-cranial disease control rate at Week 24 | 75.0 (34.9 to 96.8) | 70.6 (44.0 to 89.7) | 60.6 (42.1 to 77.1) | 62.2 (46.5 to 76.2) | 48.6 (31.9 to 65.6) | 52.0 (31.3 to 72.2) | 43.8 (19.8 to 70.1) |
TTP on the last prior therapy was defined as time from the first dose date of the last prior treatment regimen to the date of progression. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose.
| Months | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) |
|---|---|---|---|---|
| Prior systemic therapy before PF-06463922 | 11.5 (7.2 to 19.6) | 12.8 (10.9 to 16.9) | 10.2 (7.6 to 15.9) | 3.7 (2.1 to 6.4) |
| Prior ALK+/ROS1+ TKI treatment | 11.5 (7.2 to 19.6) | 13.8 (11.2 to 18.1) | 12.1 (7.9 to 16.4) | 3.7 (2.1 to 6.6) |
| Prior systemic therapy other than ALK+/ROS1+ TKI | 19.6 (16.1 to NA) | 8.5 (5.0 to 12.6) | 5.0 (3.1 to 10.0) | 5.6 (3.5 to 11.2) |
Time to progression (TTP) was defined as the time from the first dose of study treatment to the first documentation of objective PD. Intracranial TTP was defined as the time from the first dose of study treatment to the date of the first documentation of objective progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.
| Months | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|
| TTP | 17.7 (12.5 to 40.5) | 20.6 (5.5 to NA) | 8.2 (5.5 to 12.5) | 8.4 (5.6 to 13.7) | 5.6 (4.0 to 8.3) | 12.5 (8.2 to 26.2) | 5.7 (4.1 to 8.3) |
| Intracranial TTP | NA (NA to NA) | NA (NA to NA) | NA (15.0 to NA) | 22.1 (15.7 to NA) | 16.4 (12.7 to NA) | NA (34.5 to NA) | NA (6.9 to NA) |
Probability of first event being CNS progression, non-CNS progression, or death was evaluated with competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to analysis set. Time to first event being Competing Event (either "CNS progression" or "non CNS progression" or "Death") = time from first dose until date of that specific event. Participants not known to have any of Competing Events were censored on date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as competing cause of failure for analysis of other type of events. For each type of event, cumulative incidence function corresponding to nearest time point preceding 1 year is presented. PD:20% or more increase in SLD of target lesion relative to baseline or smallest SLD (nadir) recorded since first dose. SLD must demonstrate absolute increase of atleast 5mm(\>=5 mm) relative to baseline or smallest SLD (nadir) recorded since first dose.
| Probability of events | Phase 2 ITT Population |
|---|---|
| CNS progression | 0.179 |
| Non CNS progression | 0.325 |
| Death | 0.055 |
PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.
| Months | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) (Phase 2 and DDI Substudy) | 16.6 (11.8 to 28.3) | 20.6 (5.5 to NA) | 6.9 (5.5 to 11.0) | 7.3 (4.2 to 11.1) | 5.5 (3.9 to 8.2) | 9.9 (5.5 to 21.0) | 5.7 (4.0 to 7.1) |
OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.
| Months | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|
| Overall Survival (Phase 2 and DDI Substudy) | NA (NA to NA) | 52.5 (24.4 to NA) | NA (38.5 to NA) | 18.7 (15.1 to 34.1) | 20.4 (10.5 to 31.6) | 49.7 (21.0 to NA) | 19.8 (11.1 to NA) |
Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.
| ng/mL | Phase 2 and Japan LIC PK Analysis Set |
|---|---|
| Day -7 | 695.2 ± 40 |
| Cycle 1 Day 15 | 576.5 ± 42 |
Tmax of PF-06463922 was observed directly from data as time of first occurrence.
| Hours | Phase 2 and Japan LIC PK Analysis Set |
|---|---|
| Day -7 | 1.15 (0.50 to 4.02) |
| Cycle 1 Day 15 | 1.96 (0.50 to 22.7) |
AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.
| ng*hour/mL | Phase 2 and Japan LIC PK Analysis Set |
|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2) | 9088 ± 35 |
Tau refers to the dosing interval, and it equals to 24 hours for QD dosing which was adopted in Phase 2. AUCtau was determined using linear/log trapezoidal method.
| ng*hour/mL | Phase 2 and Japan LIC PK Analysis Set |
|---|---|
| Day -7 | 5308 ± 36 |
| Cycle 1 Day 15 | 5650 ± 39 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
| Liter/hour | Phase 2 and Japan LIC PK Analysis Set |
|---|---|
| Day -7 | 11.01 ± 35 |
| Cycle 1 Day 15 | 17.70 ± 39 |
Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.
| Liters | Phase 2 and Japan LIC PK Analysis Set |
|---|---|
| Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2) | 351.5 ± 37 |
Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.
| Hours | Phase 2 and Japan LIC PK Analysis Set |
|---|---|
| Terminal Half-Life of PF-06463922 (Phase 2) | 23.58 ± 9.3743 |
Rac was calculated as Day 15 AUCtau/Day -7 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2).
| Ratio | Phase 2 and Japan LIC PK Analysis Set |
|---|---|
| Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2) | 1.082 ± 0.42701 |
Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
| Ratio | Phase 2 and Japan LIC PK Analysis Set |
|---|---|
| Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2) | 0.6577 ± 0.28627 |
Plasma CNA samples were analyzed for ALK kinase domain mutations by Next Generation Sequencing (NGS). Number of participants with one or more ALK mutations is presented.
| Participants | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) |
|---|---|---|---|---|---|
| Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2) | 0 | 6 | 8 | 17 | 14 |
Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.
| Participants | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) |
|---|---|---|---|---|---|
| Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2) | 0 | 7 | 8 | 12 | 13 |
European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
| Participants | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|
| Improved in global QoL | 17 | 11 | 18 | 25 | 17 | 19 | 12 |
| Stable in global QoL | 10 | 12 | 24 | 22 | 16 | 15 | 18 |
| Worsened in global QoL | 3 | 3 | 13 | 13 | 10 | 6 | 2 |
| Missing for global QoL | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in physical functioning | 11 | 8 | 13 | 24 | 8 | 11 | 5 |
| Stable in physical functioning | 13 | 17 | 38 | 24 | 25 | 23 | 23 |
| Worsened in physical functioning | 6 | 1 | 4 | 12 | 10 | 6 | 4 |
| Missing for physical functioning | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in role functioning | 12 | 7 | 15 | 25 | 18 | 17 | 10 |
| Stable in role functioning | 9 | 16 | 33 | 18 | 13 | 17 | 15 |
| Worsened in role functioning | 9 | 3 | 7 | 17 | 12 | 5 | 7 |
| Missing for role functioning | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Improved in emotional functioning | 13 | 12 | 13 | 20 | 17 | 16 | 10 |
| Stable in emotional functioning | 13 | 14 | 32 | 34 | 20 | 22 | 20 |
| Worsened in emotional functioning | 4 | 0 | 10 | 6 | 6 | 2 | 2 |
| Missing for emotional functioning | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in cognitive functioning | 9 | 4 | 5 | 12 | 12 | 12 | 9 |
| Stable in cognitive functioning | 12 | 14 | 36 | 34 | 19 | 20 | 11 |
| Worsened in cognitive functioning | 9 | 8 | 14 | 14 | 12 | 8 | 12 |
| Missing for cognitive functioning | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in social functioning | 14 | 7 | 16 | 20 | 11 | 13 | 13 |
| Stable in social functioning | 11 | 16 | 33 | 29 | 21 | 18 | 13 |
| Worsened in social functioning | 5 | 3 | 6 | 11 | 11 | 9 | 6 |
| Missing for social functioning | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in fatigue | 18 | 14 | 22 | 28 | 26 | 16 | 17 |
| Stable in fatigue | 8 | 11 | 25 | 23 | 9 | 20 | 9 |
| Worsened in fatigue | 4 | 1 | 8 | 9 | 8 | 4 | 6 |
| Missing for fatigue | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in nausea and vomiting | 8 | 5 | 10 | 16 | 13 | 10 | 6 |
| Stable in nausea and vomiting | 22 | 21 | 44 | 39 | 28 | 28 | 24 |
| Worsened in nausea and vomiting | 0 | 0 | 1 | 5 | 2 | 2 | 2 |
| Missing for nausea and vomiting | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in pain | 13 | 10 | 20 | 23 | 19 | 21 | 14 |
| Stable in pain | 10 | 14 | 25 | 28 | 19 | 12 | 13 |
| Worsened in pain | 7 | 2 | 10 | 9 | 5 | 7 | 5 |
| Missing for pain | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in dyspnea | 16 | 10 | 10 | 23 | 14 | 14 | 9 |
| Stable in dyspnea | 10 | 14 | 33 | 22 | 18 | 17 | 15 |
| Worsened in dyspnea | 4 | 2 | 12 | 15 | 11 | 9 | 8 |
| Missing for dyspnea | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in insomnia | 20 | 8 | 18 | 30 | 21 | 19 | 12 |
| Stable in insomnia | 9 | 13 | 28 | 22 | 16 | 18 | 15 |
| Worsened in insomnia | 1 | 5 | 9 | 8 | 6 | 3 | 5 |
| Missing for insomnia | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in appetite loss | 14 | 4 | 18 | 29 | 22 | 20 | 10 |
| Stable in appetite loss | 16 | 22 | 36 | 26 | 21 | 20 | 20 |
| Worsened in appetite loss | 0 | 0 | 1 | 5 | 0 | 0 | 2 |
| Missing for appetite loss | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in constipation | 10 | 5 | 9 | 16 | 11 | 13 | 10 |
| Stable in constipation | 14 | 19 | 33 | 33 | 29 | 22 | 12 |
| Worsened in constipation | 6 | 2 | 13 | 11 | 3 | 5 | 10 |
| Missing for constipation | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in diarrhea | 5 | 3 | 10 | 10 | 10 | 8 | 6 |
| Stable in diarrhea | 18 | 21 | 40 | 39 | 27 | 28 | 21 |
| Worsened in diarrhea | 7 | 2 | 5 | 11 | 6 | 4 | 5 |
| Missing for diarrhea | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Improved in financial difficulties | 10 | 6 | 11 | 13 | 10 | 10 | 9 |
| Stable in financial difficulties | 17 | 19 | 34 | 38 | 22 | 26 | 16 |
| Worsened in financial difficulties | 3 | 1 | 10 | 9 | 11 | 4 | 7 |
| Missing for financial difficulties | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
| Participants | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|
| Improved in dyspnea | 11 | 5 | 9 | 21 | 12 | 12 | 6 |
| Stable in dyspnea | 16 | 18 | 36 | 25 | 21 | 23 | 18 |
| Worsened in dyspnea | 3 | 3 | 10 | 14 | 9 | 6 | 8 |
| Missing-dyspnea | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Improved in coughing | 18 | 9 | 22 | 26 | 18 | 17 | 16 |
| Stable in coughing | 9 | 13 | 26 | 28 | 15 | 18 | 15 |
| Worsened in coughing | 3 | 4 | 7 | 6 | 9 | 6 | 1 |
| Missing-coughing | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Improved in hemoptysis | 4 | 0 | 7 | 5 | 5 | 4 | 1 |
| Stable in hemoptysis | 24 | 25 | 47 | 52 | 34 | 36 | 31 |
| Worsened in hemoptysis | 2 | 1 | 1 | 3 | 3 | 1 | 0 |
| Missing-hemoptysis | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Improved in sore mouth | 0 | 2 | 4 | 9 | 2 | 5 | 4 |
| Stable in sore mouth | 25 | 20 | 44 | 41 | 33 | 28 | 26 |
| Worsened in sore mouth | 5 | 4 | 7 | 10 | 7 | 8 | 2 |
| Missing-sore mouth | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Improved in dysphagia | 3 | 1 | 3 | 7 | 4 | 5 | 3 |
| Stable in dysphagia | 23 | 24 | 46 | 48 | 33 | 30 | 27 |
| Worsened in dysphagia | 4 | 1 | 6 | 5 | 5 | 6 | 2 |
| Missing-dysphagia | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Improved in peripheral neuropathy | 4 | 5 | 9 | 5 | 6 | 9 | 9 |
| Stable in peripheral neuropathy | 10 | 13 | 27 | 33 | 22 | 18 | 16 |
| Worsened in peripheral neuropathy | 16 | 8 | 19 | 22 | 14 | 14 | 7 |
| Missing-peripheral neuropathy | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Improved in alopecia | 2 | 1 | 2 | 10 | 10 | 9 | 4 |
| Stable in alopecia | 18 | 22 | 41 | 40 | 24 | 27 | 21 |
| Worsened in alopecia | 10 | 3 | 12 | 10 | 8 | 5 | 7 |
| Missing-alopecia | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Improved in chest pain | 11 | 7 | 13 | 18 | 14 | 14 | 13 |
| Stable in chest pain | 17 | 17 | 35 | 33 | 25 | 24 | 17 |
| Worsened in chest pain | 2 | 2 | 6 | 9 | 3 | 3 | 2 |
| Missing-chest pain | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Improved in arm or shoulder pain | 10 | 5 | 14 | 14 | 12 | 12 | 9 |
| Stable in arm or shoulder pain | 15 | 19 | 30 | 36 | 21 | 22 | 19 |
| Worsened in arm or shoulder pain | 5 | 2 | 11 | 10 | 9 | 7 | 4 |
| Missing- arm or shoulder pain | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Improved in pain in other parts | 9 | 6 | 17 | 20 | 15 | 17 | 9 |
| Stable in pain in other parts | 14 | 15 | 23 | 24 | 9 | 18 | 10 |
| Worsened in pain in other parts | 7 | 5 | 15 | 16 | 17 | 6 | 12 |
| Missing-Pain in other parts | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
AE: any untoward medical occurrence in clinical investigation participant administered a product or medical device, regardless of causal relationship to study treatment. Treatment-emergent AEs (TEAEs): AEs which occurred for first time during effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs): any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of ability to conduction normal life function). AEs included SAEs and non-serious AEs. Severity was graded as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.Grade1: mild, Grade2: moderate, Grade3: severe, Grade4: Life threatening consequences; urgent intervention indicated, Grade 5: death related to AE.
| Participants | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AEs (all causality) | 3 | 3 | 3 | 12 | 17 | 3 | 3 | 3 | 3 | 4 | 30 | 27 | 59 | 65 | 46 | 47 | 32 |
| AEs (treatment-related) | 3 | 3 | 3 | 11 | 16 | 3 | 3 | 1 | 3 | 4 | 30 | 27 | 56 | 61 | 43 | 45 | 31 |
| SAEs (all causality) | 3 | 2 | 1 | 6 | 10 | 3 | 2 | 2 | 2 | 2 | 15 | 11 | 34 | 31 | 23 | 21 | 13 |
| SAEs (treatment-related) | 1 | 1 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 1 | 3 | 0 | 8 | 6 | 6 | 4 | 1 |
| Grade 3 or 4 (all causality) | 3 | 3 | 0 | 6 | 12 | 3 | 2 | 2 | 1 | 4 | 22 | 22 | 43 | 50 | 36 | 36 | 24 |
| Grade 3 or 4 (treatment-related) | 2 | 2 | 0 | 3 | 6 | 2 | 0 | 0 | 1 | 3 | 13 | 15 | 31 | 31 | 22 | 25 | 16 |
| Grade 5 (all causality) | 1 | 1 | 0 | 1 | 4 | 2 | 0 | 0 | 1 | 0 | 3 | 3 | 10 | 11 | 9 | 7 | 5 |
| Grade 5 (treatment-related) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils and absolute basophils. Hematology parameters with any abnormalities were reported in this outcome measure.
| Participants | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | 3 | 3 | 3 | 10 | 16 | 3 | 3 | 3 | 3 | 4 | 24 | 22 | 51 | 52 | 35 | 34 | 25 |
| Hemoglobin increased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 1 | 1 |
| Lymphocyte count decreased | 2 | 2 | 2 | 7 | 4 | 3 | 3 | 0 | 0 | 2 | 12 | 14 | 30 | 31 | 21 | 26 | 15 |
| Lymphocyte count increased | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 4 | 3 | 6 | 1 | 1 | 0 | 2 |
| Neutrophil count decreased | 1 | 0 | 0 | 4 | 2 | 0 | 1 | 0 | 0 | 1 | 7 | 3 | 8 | 10 | 2 | 7 | 3 |
| Platelet count decreased | 2 | 2 | 0 | 4 | 5 | 1 | 0 | 0 | 0 | 1 | 8 | 10 | 18 | 12 | 13 | 13 | 8 |
| White blood cell decreased | 2 | 1 | 0 | 4 | 2 | 2 | 2 | 0 | 0 | 1 | 9 | 5 | 9 | 13 | 8 | 10 | 4 |
Chemistry evaluation included alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), blood bilirubin, creatine phosphokinase (CPK), creatinine, gamma-glutamyl transferase (GGT), calcium, sodium, potassium, magnesium, albumin, glucose (non-fasted), albumin, phosphorus or phosphate, serum amylase and lipase.
| Participants | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT increased | 2 | 1 | 1 | 6 | 9 | 2 | 2 | 0 | 0 | 3 | 13 | 15 | 25 | 25 | 16 | 15 | 10 |
| Alkaline phosphatase increased | 1 | 1 | 3 | 6 | 10 | 3 | 1 | 0 | 2 | 3 | 10 | 13 | 29 | 27 | 25 | 14 | 9 |
| AST increased | 2 | 2 | 2 | 5 | 8 | 2 | 2 | 0 | 1 | 3 | 16 | 15 | 36 | 33 | 21 | 18 | 11 |
| Blood bilirubin increased | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 3 | 1 | 2 | 1 | 1 |
| CPK increased | — | — | — | — | 1 | 1 | — | — | 1 | — | 2 | 1 | 3 | 1 | — | 2 | 1 |
| Creatinine increased | 3 | 2 | 3 | 10 | 13 | 3 | 3 | 2 | 2 | 3 | 28 | 22 | 40 | 48 | 34 | 37 | 20 |
| GGT increased | 0 | — | — | — | 1 | 0 | 1 | — | 0 | 2 | 1 | 3 | 2 | 1 | 0 | 1 | 0 |
| Hypercalcemia | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 1 | 8 | 4 | 7 | 8 | 4 | 2 | 5 |
| Hyperglycemia | 3 | 3 | 2 | 7 | 8 | 2 | 1 | 1 | 2 | 1 | 17 | 18 | 37 | 48 | 34 | 31 | 23 |
| Hyperkalemia | 0 | 1 | 2 | 3 | 6 | 1 | 1 | 1 | 1 | 2 | 11 | 13 | 21 | 13 | 7 | 6 | 5 |
| Hypermagnesemia | 2 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 2 | 2 | 1 | 4 | 0 |
| Hypernatremia | 0 | 1 | 0 | 0 | 4 | 2 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 5 | 4 | 5 | 3 |
| Hypoalbuminemia | 2 | 1 | 3 | 4 | 7 | 3 | 1 | 1 | 3 | 1 | 19 | 20 | 37 | 43 | 32 | 29 | 18 |
| Hypocalcemia | 1 | 0 | 1 | 4 | 5 | 2 | 1 | 0 | 0 | 1 | 5 | 5 | 16 | 9 | 6 | 12 | 6 |
| Hypoglycemia | 0 | 0 | 1 | 3 | 4 | 0 | 1 | 0 | 1 | 0 | 1 | 4 | 10 | 9 | 6 | 3 | 6 |
| Hypokalemia | 0 | 0 | 2 | 4 | 3 | 3 | 1 | 1 | 0 | 2 | 11 | 2 | 10 | 12 | 8 | 14 | 7 |
| Hypomagnesemia | 0 | 1 | 2 | 4 | 2 | 3 | 0 | 1 | 1 | 3 | 6 | 9 | 23 | 20 | 16 | 15 | 15 |
| Hyponatremia | 2 | 1 | 1 | 2 | 4 | 1 | 1 | 0 | 2 | 2 | 7 | 9 | 15 | 23 | 12 | 12 | 10 |
| Hypophosphatemia | 1 | 2 | 0 | 3 | 3 | 2 | 1 | 1 | 2 | 1 | 8 | 9 | 23 | 19 | 8 | 15 | 9 |
| Lipase increased | 3 | 0 | 0 | 8 | 6 | 0 | 1 | 0 | 2 | 2 | 10 | 7 | 14 | 16 | 15 | 18 | 7 |
| Serum amylase increased | 3 | 0 | 0 | 2 | 5 | 0 | 1 | 0 | 0 | 2 | 13 | 6 | 18 | 20 | 11 | 15 | 4 |
Coagulation evaluation included activated partial thromboplastin time, international normalized ratio (INR), and prothrombin time. Lipid evaluation included Cholesterol and triglycerides.
| Participants | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Activated partial thromboplastin time prolonged | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 | 1 | 3 | 4 | 2 |
| Cholesterol high | 2 | 2 | 2 | 10 | 16 | 2 | 3 | 3 | 2 | 3 | 30 | 26 | 58 | 64 | 45 | 44 | 31 |
| Hypertriglyceridemia | 0 | 2 | 2 | 11 | 16 | 2 | 3 | 2 | 1 | 3 | 30 | 26 | 56 | 61 | 45 | 43 | 31 |
| INR increased | 2 | 1 | 1 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 6 | 2 | 7 | 3 |
| Prothrombin time | 2 | 1 | 1 | 3 | 3 | 1 | 0 | 0 | 1 | 1 | 1 | 3 | 6 | 6 | 3 | 6 | 6 |
Blood pressure (BP), including systolic BP (SBP) and diastolic BP (DBP), and pulse rate were recorded in sitting position. Body weight was also measured.
| Participants | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Increase in sitting SBP >=40 mmHg | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 1 | 0 | 9 | 7 | 10 | 10 | 5 | 4 | 4 |
| Increase in sitting SBP >=60 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Decrease in sitting SBP >=40 mmHg | 0 | 0 | 0 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 2 | 2 | 3 | 1 |
| Decrease in sitting SBP >=60 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Increase in sitting DBP >=20 mmHg | 0 | 2 | 0 | 0 | 7 | 3 | 1 | 0 | 1 | 0 | 11 | 12 | 21 | 15 | 15 | 12 | 7 |
| Increase in sitting DBP >=40 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 1 | 0 | 2 | 0 |
| Decrease in sitting DBP >=20 mmHg | 2 | 1 | 0 | 5 | 3 | 2 | 2 | 0 | 1 | 2 | 9 | 5 | 15 | 10 | 10 | 9 | 8 |
| Decrease in sitting DBP >=40 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Sitting pulse rate <50 bpm | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 5 | 1 | 0 | 2 | 2 |
| Sitting pulse rate >120 bpm | 0 | 0 | 1 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 5 | 9 | 4 | 2 | 3 |
| Increase in sitting pulse rate >=30 bpm | 0 | 1 | 0 | 2 | 7 | 1 | 0 | 0 | 0 | 1 | 0 | 7 | 14 | 19 | 17 | 17 | 8 |
| Decrease in sitting pulse rate >=30 bpm | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 1 | 2 | 11 | 2 | 8 | 7 | 3 | 5 | 4 |
| Increase in weight: 10% to <20% | 1 | 0 | 0 | 8 | 6 | 2 | 2 | 0 | 0 | 0 | 9 | 14 | 17 | 15 | 11 | 14 | 9 |
| Increase in weight: >=20% | 0 | 2 | 1 | 1 | 5 | 1 | 0 | 0 | 1 | 1 | 12 | 2 | 10 | 16 | 9 | 9 | 3 |
| Decrease in weight >=10% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 3 | 4 | 2 | 2 | 1 |
Left Ventricular Ejection Fraction (LVEF) was determined by echocardiogram. Baseline was defined as the measurement prior to the first dose of study treatment.
| Participants | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1, Phase 2 and DDI Sub-study) | 1 | 0 | 1 | 3 | 5 | 2 | 1 | 0 | 0 | 2 | 4 | 2 | 13 | 14 | 3 | 5 | 2 |
Triplicate 12-lead electrocardiograms (ECGs) were performed approximately 2 minutes apart to determine mean QTc interval (QT interval corrected for heart rate). QT interval was corrected for heart rate using Fridericia's formula to provide QTcF. Absolute values and changes from baseline were summarized according to pre-defined criteria. Baseline was defined as the last evaluation on or prior to the first dose of study treatment.
| Participants | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Sub-study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QTcF: 450 to <480 msec | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 0 | 1 | 5 | 8 | 11 | 9 | 13 | 9 | 7 |
| QTcF: 480 to <500 msec | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 0 | 1 | 1 | 1 |
| QTcF: >=500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
| QTcF Increase: 30 to <60 msec | 0 | 0 | 1 | 3 | 3 | 0 | 0 | 1 | 0 | 1 | 10 | 8 | 18 | 20 | 7 | 12 | 7 |
| QTcF: >=60 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 3 | 1 | 1 |
The Columbia Suicide Severity Rating Scale (C-SSRS) was used to analyze participants' suicidal ideation and behavior, and it is a unique, simple and short method of assessing both behavior and ideation that tracks all suicidal events and provides a summary of suicidality. It assesses the lethality of attempts and other features of ideation (frequency, duration, controllability, reasons for ideation and deterrents), all of which are significantly predictive of completed suicide. Maximum score of 4 or 5 indicates maximum suicidal ideation and minimum score of "0" indicates no suicidal ideation.
| Participants | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) |
|---|---|---|---|---|---|---|
| Suicidal ideation | 1 | 0 | 2 | 1 | 1 | 2 |
| Suicidal behavior | 0 | 0 | 0 | 0 | 0 | 1 |
The Beck Depression Inventory (BDI)-II is a 21-item self-report scale, with each item rated by participants on a 4-point scale (ranging from 0-3, where 0 indicated lowest depression and 3 indicated severe depression). The scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike, pessimism, and poor concentration) as well as somatic signs (appetite, sleep, fatigue and libido). Scores were obtained by adding up the total points from the series of answers. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.
| Units on a scale | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) |
|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | -2.59 (-4.82 to -0.37) | -3.27 (-5.52 to -1.01) | -2.26 (-3.77 to -0.76) | -2.17 (-3.89 to -0.46) | -1.52 (-3.60 to 0.56) | -2.43 (-4.57 to -0.29) |
| Cycle 3 Day 1 | -3.34 (-5.57 to -1.12) | -3.18 (-5.43 to -0.93) | -3.03 (-4.55 to -1.51) | -3.10 (-4.85 to -1.35) | -0.46 (-2.61 to 1.69) | -1.24 (-3.37 to 0.90) |
| Cycle 4 Day 1 | -3.84 (-6.07 to -1.62) | -4.10 (-6.38 to -1.82) | -2.59 (-4.14 to -1.05) | -1.95 (-3.72 to -0.19) | -1.19 (-3.38 to 1.01) | -1.94 (-4.12 to 0.24) |
| Cycle 5 Day 1 | -4.47 (-6.69 to -2.24) | -3.96 (-6.27 to -1.66) | -2.75 (-4.33 to -1.16) | -3.03 (-4.82 to -1.25) | -1.51 (-3.74 to 0.72) | -1.25 (-3.46 to 0.95) |
| Cycle 6 Day 1 | -3.51 (-5.73 to -1.28) | -4.25 (-6.56 to -1.94) | -3.31 (-4.90 to -1.72) | -3.79 (-5.61 to -1.98) | -0.42 (-2.64 to 1.81) | -0.29 (-2.54 to 1.96) |
| Cycle 8 Day 1 | -4.17 (-6.41 to -1.92) | -4.86 (-7.23 to -2.50) | -2.26 (-3.86 to -0.66) | -4.06 (-5.90 to -2.22) | -1.09 (-3.34 to 1.17) | 0.17 (-2.10 to 2.45) |
| Cycle 10 Day 1 | -3.09 (-5.38 to -0.80) | -4.92 (-7.28 to -2.55) | -1.94 (-3.54 to -0.34) | -4.27 (-6.14 to -2.39) | -2.97 (-5.29 to -0.66) | -0.19 (-2.60 to 2.22) |
| Cycle 12 Day 1 | -3.95 (-6.30 to -1.61) | -5.60 (-7.97 to -3.24) | -0.72 (-2.40 to 0.95) | -4.80 (-6.83 to -2.77) | -1.94 (-4.29 to 0.42) | -1.40 (-3.81 to 1.01) |
| Cycle 14 Day 1 | -3.81 (-6.18 to -1.43) | -5.80 (-8.35 to -3.25) | -2.58 (-4.41 to -0.76) | -4.29 (-6.41 to -2.17) | -1.73 (-4.40 to 0.94) | -0.08 (-2.59 to 2.42) |
| Cycle 16 Day 1 | -1.75 (-4.40 to 0.89) | -4.61 (-7.51 to -1.71) | -2.15 (-4.35 to 0.06) | -4.65 (-6.90 to -2.41) | -2.22 (-5.50 to 1.07) | 0.03 (-2.65 to 2.71) |
| Cycle 18 Day 1 | -4.49 (-7.49 to -1.49) | -7.02 (-10.59 to -3.46) | -1.96 (-4.22 to 0.31) | -2.86 (-5.21 to -0.51) | -1.11 (-8.25 to 6.03) | 1.88 (-1.66 to 5.41) |
| Cycle 20 Day 1 | -5.01 (-8.55 to -1.46) | -5.17 (-9.06 to -1.29) | -1.82 (-4.70 to 1.06) | -3.63 (-6.31 to -0.95) | — | 1.88 (-1.66 to 5.41) |
| Cycle 22 Day 1 | -2.93 (-6.79 to 0.94) | -4.63 (-9.00 to -0.26) | -2.36 (-5.68 to 0.96) | -5.50 (-8.87 to -2.12) | — | -2.39 (-6.73 to 1.94) |
| Cycle 24 Day 1 | -7.31 (-11.66 to -2.96) | -5.63 (-10.00 to -1.26) | -2.88 (-7.04 to 1.28) | -3.89 (-8.10 to 0.32) | — | 2.27 (-2.06 to 6.61) |
| Cycle 26 Day 1 | -5.50 (-10.67 to -0.33) | — | -3.03 (-10.01 to 3.95) | -4.30 (-11.31 to 2.70) | — | — |
| End of treatment | -4.77 (-9.23 to -0.32) | -0.73 (-5.61 to 4.15) | -2.55 (-5.28 to 0.18) | -3.22 (-5.49 to -0.95) | 0.74 (-2.70 to 4.17) | -2.08 (-5.65 to 1.50) |
The Detection Test is a measure of psychomotor function and uses a well validated simple reaction time paradigm with playing card stimuli. In this test, the on-screen instructions ask: "Has the card turned over?". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as the card flips over the participant must press "Yes". The participant is encouraged to work as quickly as they can and be as accurate as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
| Units on a scale | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) |
|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | 0.01 (-0.04 to 0.05) | 0.04 (-0.01 to 0.08) | -0.01 (-0.04 to 0.02) | 0.02 (-0.01 to 0.05) | -0.02 (-0.05 to 0.02) | 0.01 (-0.03 to 0.05) |
| Cycle 3 Day 1 | -0.01 (-0.05 to 0.03) | 0.01 (-0.03 to 0.05) | 0.01 (-0.02 to 0.04) | -0.01 (-0.04 to 0.02) | -0.01 (-0.05 to 0.02) | -0.01 (-0.05 to 0.03) |
| Cycle 4 Day 1 | 0.03 (-0.02 to 0.07) | 0.00 (-0.04 to 0.04) | -0.03 (-0.06 to 0.00) | -0.02 (-0.05 to 0.01) | -0.04 (-0.07 to -0.00) | -0.01 (-0.06 to 0.03) |
| Cycle 5 Day 1 | -0.01 (-0.05 to 0.03) | -0.01 (-0.06 to 0.03) | -0.00 (-0.03 to 0.03) | 0.00 (-0.03 to 0.03) | -0.04 (-0.08 to -0.01) | -0.04 (-0.08 to 0.00) |
| Cycle 6 Day 1 | -0.03 (-0.07 to 0.01) | 0.01 (-0.03 to 0.06) | -0.02 (-0.05 to 0.01) | -0.00 (-0.04 to 0.03) | -0.01 (-0.05 to 0.02) | -0.02 (-0.07 to 0.02) |
| Cycle 8 Day 1 | -0.02 (-0.06 to 0.02) | 0.00 (-0.04 to 0.05) | -0.02 (-0.05 to 0.01) | -0.03 (-0.06 to 0.01) | -0.04 (-0.07 to 0.00) | 0.00 (-0.04 to 0.05) |
| Cycle 10 Day 1 | -0.02 (-0.06 to 0.02) | 0.03 (-0.01 to 0.08) | -0.02 (-0.06 to 0.01) | -0.01 (-0.05 to 0.02) | -0.05 (-0.09 to -0.01) | -0.04 (-0.08 to 0.01) |
| Cycle 12 Day 1 | -0.04 (-0.08 to 0.01) | -0.00 (-0.05 to 0.04) | -0.02 (-0.06 to 0.02) | -0.03 (-0.06 to 0.01) | -0.08 (-0.13 to -0.04) | -0.01 (-0.05 to 0.04) |
| Cycle 14 Day 1 | 0.02 (-0.04 to 0.07) | 0.02 (-0.03 to 0.08) | -0.05 (-0.09 to -0.01) | -0.04 (-0.08 to -0.00) | -0.02 (-0.07 to 0.04) | 0.01 (-0.05 to 0.06) |
| Cycle 16 Day 1 | -0.03 (-0.09 to 0.03) | 0.01 (-0.05 to 0.07) | 0.02 (-0.03 to 0.07) | -0.03 (-0.08 to 0.01) | -0.04 (-0.14 to 0.06) | -0.01 (-0.07 to 0.06) |
| Cycle 18 Day 1 | 0.09 (0.01 to 0.18) | -0.02 (-0.09 to 0.05) | -0.03 (-0.09 to 0.02) | -0.06 (-0.11 to -0.01) | -0.09 (-0.23 to 0.04) | -0.01 (-0.08 to 0.05) |
| Cycle 20 Day 1 | 0.07 (-0.03 to 0.17) | 0.02 (-0.06 to 0.09) | 0.01 (-0.06 to 0.08) | -0.09 (-0.16 to -0.03) | — | -0.03 (-0.11 to 0.04) |
| Cycle 22 Day 1 | -0.02 (-0.12 to 0.08) | -0.02 (-0.10 to 0.07) | 0.00 (-0.08 to 0.08) | -0.08 (-0.16 to 0.00) | — | -0.05 (-0.13 to 0.03) |
| Cycle 24 Day 1 | 0.03 (-0.11 to 0.16) | — | — | -0.06 (-0.20 to 0.07) | — | — |
| End of treatment | -0.04 (-0.13 to 0.04) | -0.01 (-0.10 to 0.08) | -0.02 (-0.08 to 0.04) | -0.05 (-0.10 to -0.00) | -0.07 (-0.14 to -0.01) | -0.05 (-0.12 to 0.03) |
The Identification Test is a measure of visual attention and uses a well validated choice reaction time paradigm with playing card stimuli. In this task, the playing cards are all red or black jokers. The on-screen instructions ask: "Is the card red?". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as it flips over the participant must decide whether the card is red or not. If it is red the participant should press "Yes", and if it is not red the participant should press "No". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
| Units on a scale | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) |
|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | -0.02 (-0.05 to 0.01) | -0.02 (-0.05 to 0.01) | -0.01 (-0.03 to 0.00) | -0.01 (-0.03 to 0.01) | -0.02 (-0.04 to 0.01) | -0.01 (-0.04 to 0.02) |
| Cycle 3 Day 1 | -0.01 (-0.04 to 0.02) | -0.01 (-0.04 to 0.02) | -0.02 (-0.04 to 0.00) | -0.02 (-0.04 to 0.00) | -0.02 (-0.05 to 0.00) | -0.01 (-0.04 to 0.02) |
| Cycle 4 Day 1 | -0.02 (-0.05 to 0.01) | -0.01 (-0.04 to 0.01) | -0.02 (-0.04 to 0.00) | -0.03 (-0.05 to -0.01) | -0.05 (-0.08 to -0.03) | -0.02 (-0.04 to 0.01) |
| Cycle 5 Day 1 | -0.03 (-0.06 to -0.00) | -0.02 (-0.05 to 0.01) | -0.03 (-0.05 to -0.00) | -0.02 (-0.04 to 0.01) | -0.05 (-0.07 to -0.02) | -0.02 (-0.05 to 0.00) |
| Cycle 6 Day 1 | -0.04 (-0.07 to -0.01) | -0.02 (-0.05 to 0.01) | -0.02 (-0.04 to 0.00) | -0.03 (-0.06 to -0.01) | -0.03 (-0.06 to -0.01) | -0.03 (-0.06 to -0.00) |
| Cycle 8 Day 1 | -0.03 (-0.06 to -0.00) | -0.02 (-0.05 to 0.01) | -0.03 (-0.05 to -0.01) | -0.03 (-0.05 to -0.01) | -0.05 (-0.07 to -0.02) | -0.03 (-0.06 to 0.00) |
| Cycle 10 Day 1 | -0.03 (-0.06 to 0.00) | -0.01 (-0.04 to 0.02) | -0.03 (-0.05 to -0.01) | -0.02 (-0.05 to 0.00) | -0.05 (-0.08 to -0.02) | -0.03 (-0.06 to 0.00) |
| Cycle 12 Day 1 | -0.05 (-0.08 to -0.02) | -0.04 (-0.07 to -0.01) | -0.04 (-0.06 to -0.01) | -0.04 (-0.07 to -0.01) | -0.06 (-0.09 to -0.03) | -0.03 (-0.06 to 0.00) |
| Cycle 14 Day 1 | -0.04 (-0.08 to 0.00) | -0.04 (-0.07 to -0.00) | -0.03 (-0.06 to -0.00) | -0.04 (-0.07 to -0.01) | -0.04 (-0.08 to -0.00) | -0.02 (-0.06 to 0.02) |
| Cycle 16 Day 1 | -0.09 (-0.13 to -0.05) | -0.00 (-0.04 to 0.04) | -0.03 (-0.07 to 0.01) | -0.03 (-0.06 to 0.01) | -0.07 (-0.13 to 0.00) | -0.06 (-0.10 to -0.01) |
| Cycle 18 Day 1 | -0.01 (-0.06 to 0.05) | -0.05 (-0.09 to 0.00) | -0.04 (-0.08 to 0.00) | -0.07 (-0.10 to -0.03) | -0.19 (-0.29 to -0.09) | -0.01 (-0.05 to 0.04) |
| Cycle 20 Day 1 | -0.03 (-0.10 to 0.04) | -0.01 (-0.06 to 0.04) | -0.03 (-0.08 to 0.02) | -0.10 (-0.15 to -0.06) | — | -0.03 (-0.08 to 0.02) |
| Cycle 22 Day 1 | 0.04 (-0.03 to 0.11) | -0.01 (-0.07 to 0.05) | -0.06 (-0.11 to 0.00) | -0.05 (-0.11 to 0.00) | — | -0.08 (-0.14 to -0.03) |
| Cycle 24 Day 1 | 0.08 (-0.01 to 0.18) | — | — | -0.06 (-0.15 to 0.04) | — | — |
| End of treatment | -0.07 (-0.13 to -0.02) | -0.03 (-0.10 to 0.03) | -0.02 (-0.06 to 0.02) | -0.03 (-0.06 to 0.01) | -0.09 (-0.14 to -0.05) | -0.06 (-0.11 to -0.01) |
The One Back Test is a measure of working memory and uses a well validated n back paradigm with playing cards. In this task, the on-screen instructions ask: "Is the previous card the same?". A playing card is presented in the center of the screen. The participant must decide whether the card is the same as the previous card. If it is the same the participant should press "Yes", and if not press "No". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded, mean of the log10 transformed reaction times for correct responses is used to demonstrate speed of performance, and the arcsine transformation of the square root of the proportion of correct responses is used to demonstrate accuracy. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
| Units on a scale | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) |
|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | 0.01 (-0.02 to 0.05) | 0.02 (-0.01 to 0.05) | 0.02 (0.00 to 0.05) | 0.01 (-0.01 to 0.04) | 0.02 (-0.01 to 0.05) | 0.01 (-0.02 to 0.04) |
| Cycle 3 Day 1 | 0.06 (0.02 to 0.09) | 0.01 (-0.02 to 0.05) | 0.01 (-0.01 to 0.04) | 0.01 (-0.02 to 0.03) | -0.01 (-0.04 to 0.02) | -0.00 (-0.04 to 0.03) |
| Cycle 4 Day 1 | 0.04 (0.01 to 0.08) | 0.03 (-0.00 to 0.06) | 0.02 (-0.01 to 0.04) | -0.01 (-0.04 to 0.01) | -0.02 (-0.05 to 0.01) | -0.01 (-0.05 to 0.02) |
| Cycle 5 Day 1 | 0.02 (-0.01 to 0.06) | 0.03 (-0.00 to 0.07) | 0.03 (0.00 to 0.05) | -0.01 (-0.04 to 0.02) | -0.02 (-0.05 to 0.01) | 0.02 (-0.01 to 0.05) |
| Cycle 6 Day 1 | 0.03 (-0.01 to 0.06) | 0.03 (-0.00 to 0.07) | 0.03 (0.01 to 0.06) | 0.01 (-0.02 to 0.04) | -0.00 (-0.03 to 0.03) | 0.01 (-0.03 to 0.04) |
| Cycle 8 Day 1 | 0.03 (-0.01 to 0.06) | 0.02 (-0.02 to 0.06) | 0.03 (0.00 to 0.05) | 0.01 (-0.02 to 0.03) | -0.01 (-0.04 to 0.02) | 0.01 (-0.02 to 0.05) |
| Cycle 10 Day 1 | 0.07 (0.03 to 0.11) | 0.03 (-0.00 to 0.07) | 0.03 (0.00 to 0.05) | 0.02 (-0.01 to 0.05) | -0.01 (-0.05 to 0.02) | 0.01 (-0.02 to 0.05) |
| Cycle 12 Day 1 | 0.05 (0.01 to 0.08) | 0.01 (-0.03 to 0.05) | 0.02 (-0.01 to 0.05) | 0.01 (-0.02 to 0.04) | -0.00 (-0.04 to 0.03) | 0.03 (-0.01 to 0.07) |
| Cycle 14 Day 1 | 0.00 (-0.05 to 0.05) | 0.03 (-0.01 to 0.07) | 0.03 (-0.01 to 0.07) | -0.00 (-0.04 to 0.03) | 0.01 (-0.04 to 0.06) | 0.02 (-0.03 to 0.07) |
| Cycle 16 Day 1 | 0.03 (-0.03 to 0.08) | 0.05 (-0.01 to 0.10) | 0.05 (0.00 to 0.09) | -0.02 (-0.05 to 0.02) | -0.01 (-0.10 to 0.08) | 0.03 (-0.03 to 0.08) |
| Cycle 18 Day 1 | 0.02 (-0.06 to 0.09) | 0.01 (-0.04 to 0.07) | 0.06 (0.02 to 0.11) | -0.02 (-0.06 to 0.03) | -0.18 (-0.30 to -0.06) | 0.05 (-0.01 to 0.10) |
| Cycle 20 Day 1 | -0.06 (-0.15 to 0.03) | 0.07 (0.00 to 0.13) | 0.02 (-0.05 to 0.08) | -0.01 (-0.06 to 0.05) | — | 0.02 (-0.04 to 0.09) |
| Cycle 22 Day 1 | 0.02 (-0.07 to 0.11) | 0.05 (-0.02 to 0.12) | 0.04 (-0.03 to 0.11) | -0.07 (-0.14 to 0.00) | — | 0.03 (-0.04 to 0.11) |
| Cycle 24 Day 1 | 0.09 (-0.03 to 0.21) | — | — | 0.01 (-0.11 to 0.13) | — | — |
| End of treatment | -0.03 (-0.10 to 0.05) | 0.03 (-0.05 to 0.11) | 0.03 (-0.02 to 0.07) | 0.01 (-0.04 to 0.05) | -0.03 (-0.08 to 0.02) | 0.02 (-0.05 to 0.08) |
The International Shopping List task is a measure of verbal learning and uses a well validated list learning paradigm administered using a computer. High frequencies, high imagery, concrete nouns (items from a shopping list) were read to the participant at the rate of one word every 2 seconds. Once all 12 words had been read, the participant was asked to recall as many of the words as quickly as possible. The words recalled by the participant were marked on the computer screen. When the participant could recall no more words, the same list was read again. The words recalled by the participant were recorded. This was then repeated a third time. Total number of correct responses on 3 consecutive trials at a single assessment was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
| Units on a scale | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) |
|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | -0.02 (-1.89 to 1.84) | -1.13 (-2.90 to 0.64) | 0.25 (-1.01 to 1.52) | -0.45 (-1.76 to 0.86) | 0.96 (-0.50 to 2.43) | 0.16 (-1.51 to 1.83) |
| Cycle 3 Day 1 | 0.19 (-1.66 to 2.03) | -0.81 (-2.58 to 0.96) | 0.14 (-1.15 to 1.43) | -1.04 (-2.36 to 0.29) | -0.08 (-1.59 to 1.44) | -0.56 (-2.21 to 1.09) |
| Cycle 4 Day 1 | 0.58 (-1.26 to 2.42) | 0.26 (-1.54 to 2.05) | 0.28 (-1.05 to 1.61) | 0.24 (-1.12 to 1.60) | 1.30 (-0.26 to 2.86) | -0.87 (-2.59 to 0.84) |
| Cycle 5 Day 1 | 1.30 (-0.51 to 3.12) | -0.66 (-2.53 to 1.21) | 0.59 (-0.77 to 1.95) | -0.94 (-2.33 to 0.45) | 1.23 (-0.36 to 2.82) | 0.74 (-0.97 to 2.45) |
| Cycle 6 Day 1 | 0.18 (-1.64 to 1.99) | 0.81 (-1.06 to 2.68) | 0.50 (-0.87 to 1.87) | 0.08 (-1.31 to 1.47) | 0.82 (-0.83 to 2.46) | -0.51 (-2.31 to 1.29) |
| Cycle 8 Day 1 | 0.84 (-1.00 to 2.68) | 0.60 (-1.30 to 2.50) | 1.69 (0.29 to 3.08) | 0.15 (-1.27 to 1.57) | 0.44 (-1.23 to 2.11) | 1.70 (-0.11 to 3.50) |
| Cycle 10 Day 1 | 0.26 (-1.68 to 2.21) | 2.59 (0.65 to 4.52) | 0.86 (-0.56 to 2.27) | 0.13 (-1.46 to 1.72) | 2.29 (0.53 to 4.05) | 0.97 (-0.99 to 2.93) |
| Cycle 12 Day 1 | 2.87 (0.86 to 4.88) | 0.02 (-2.06 to 2.10) | 0.11 (-1.52 to 1.73) | 0.69 (-0.98 to 2.35) | 1.74 (-0.25 to 3.72) | 3.10 (1.06 to 5.14) |
| Cycle 14 Day 1 | 1.91 (-0.71 to 4.53) | 1.46 (-0.85 to 3.78) | 2.27 (0.36 to 4.17) | 0.94 (-0.86 to 2.73) | -4.43 (-7.11 to -1.75) | 2.67 (0.09 to 5.25) |
| Cycle 16 Day 1 | 4.52 (1.58 to 7.46) | 0.87 (-2.06 to 3.79) | 1.36 (-1.11 to 3.84) | 1.04 (-0.99 to 3.07) | 3.46 (-1.26 to 8.18) | 1.97 (-0.93 to 4.87) |
| Cycle 18 Day 1 | 4.77 (0.82 to 8.73) | 0.66 (-2.50 to 3.81) | -0.27 (-2.89 to 2.36) | -0.52 (-2.77 to 1.73) | -0.35 (-6.90 to 6.21) | 3.13 (0.00 to 6.27) |
| Cycle 20 Day 1 | -2.72 (-7.47 to 2.03) | -1.44 (-4.91 to 2.03) | 0.56 (-2.81 to 3.92) | 1.20 (-1.84 to 4.24) | — | 0.56 (-2.89 to 4.01) |
| Cycle 22 Day 1 | -5.72 (-10.47 to -0.97) | -0.28 (-4.22 to 3.66) | 2.17 (-1.68 to 6.01) | -0.36 (-4.21 to 3.48) | — | 3.99 (0.07 to 7.91) |
| Cycle 24 Day 1 | -8.49 (-15.06 to -1.92) | — | — | -3.35 (-9.86 to 3.16) | — | — |
| End of treatment | 1.02 (-2.99 to 5.04) | -1.62 (-5.95 to 2.71) | 0.80 (-1.80 to 3.40) | -0.27 (-2.47 to 1.92) | 2.37 (-0.54 to 5.27) | -0.60 (-4.09 to 2.89) |
This test was performed in the same way as the International Shopping List Test, with the exception that, the delayed recall condition required the participant to recall the words from the list 15 30 minutes later without having the list read again. During the recognition condition, the qualified personnel read a shopping list item that may or may not have been on the original list and the participant had to respond either affirmatively (if the item was on the original list) or negatively (if it was not). Total number of correct responses made in remembering the word list after a delay was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
| Units on a scale | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) |
|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | 0.10 (-0.85 to 1.06) | -0.84 (-1.76 to 0.08) | -0.12 (-0.77 to 0.53) | -0.59 (-1.28 to 0.09) | -0.22 (-0.96 to 0.53) | -0.25 (-1.11 to 0.62) |
| Cycle 3 Day 1 | -0.33 (-1.28 to 0.62) | -1.32 (-2.24 to -0.40) | -0.14 (-0.81 to 0.52) | -0.77 (-1.46 to -0.07) | -0.87 (-1.64 to -0.10) | -0.30 (-1.15 to 0.56) |
| Cycle 4 Day 1 | -0.44 (-1.38 to 0.50) | -0.91 (-1.86 to 0.03) | 0.03 (-0.66 to 0.72) | -0.25 (-0.97 to 0.47) | -0.02 (-0.82 to 0.78) | -1.06 (-1.95 to -0.18) |
| Cycle 5 Day 1 | -0.35 (-1.29 to 0.59) | -0.57 (-1.54 to 0.40) | 0.02 (-0.69 to 0.73) | -0.46 (-1.20 to 0.27) | 0.09 (-0.74 to 0.92) | 0.17 (-0.72 to 1.05) |
| Cycle 6 Day 1 | 0.48 (-0.46 to 1.42) | -0.38 (-1.35 to 0.59) | 0.12 (-0.59 to 0.84) | -0.22 (-0.95 to 0.52) | 0.30 (-0.55 to 1.15) | -0.28 (-1.21 to 0.66) |
| Cycle 8 Day 1 | 0.56 (-0.38 to 1.50) | -0.24 (-1.23 to 0.75) | 0.02 (-0.70 to 0.74) | -0.49 (-1.24 to 0.25) | -1.08 (-1.94 to -0.22) | -0.16 (-1.10 to 0.77) |
| Cycle 10 Day 1 | 0.29 (-0.74 to 1.31) | 0.80 (-0.22 to 1.82) | 0.54 (-0.20 to 1.28) | 0.23 (-0.61 to 1.08) | 0.25 (-0.67 to 1.16) | -0.00 (-1.02 to 1.02) |
| Cycle 12 Day 1 | 0.90 (-0.15 to 1.95) | 0.13 (-0.95 to 1.21) | 0.22 (-0.63 to 1.07) | 0.19 (-0.70 to 1.07) | 0.60 (-0.43 to 1.64) | 0.42 (-0.64 to 1.49) |
| Cycle 14 Day 1 | 0.38 (-0.99 to 1.75) | 0.06 (-1.15 to 1.27) | 1.06 (0.06 to 2.06) | 0.11 (-0.85 to 1.07) | -1.80 (-3.31 to -0.30) | 0.35 (-1.00 to 1.71) |
| Cycle 16 Day 1 | 0.89 (-0.66 to 2.43) | 0.52 (-1.02 to 2.05) | 0.68 (-0.62 to 1.98) | -0.12 (-1.22 to 0.98) | 0.40 (-2.09 to 2.88) | -0.22 (-1.75 to 1.30) |
| Cycle 18 Day 1 | 1.06 (-1.02 to 3.14) | 0.68 (-0.98 to 2.34) | 0.38 (-1.00 to 1.76) | -0.24 (-1.54 to 1.07) | -0.39 (-3.85 to 3.07) | -0.33 (-1.97 to 1.32) |
| Cycle 20 Day 1 | -1.22 (-3.73 to 1.28) | 0.16 (-1.67 to 1.98) | -0.24 (-2.01 to 1.53) | -0.18 (-1.78 to 1.43) | — | -0.70 (-2.52 to 1.11) |
| Cycle 22 Day 1 | -3.22 (-5.73 to -0.72) | 0.68 (-1.40 to 2.76) | 0.80 (-1.23 to 2.83) | -0.64 (-2.67 to 1.39) | — | 0.37 (-1.70 to 2.43) |
| Cycle 24 Day 1 | -2.43 (-5.89 to 1.04) | — | — | -0.80 (-4.25 to 2.64) | — | — |
| End of treatment | -0.87 (-2.99 to 1.24) | -2.31 (-4.58 to -0.04) | 0.52 (-0.84 to 1.89) | -0.85 (-2.06 to 0.35) | -0.19 (-1.71 to 1.34) | 0.11 (-1.72 to 1.95) |
PR Interval was determined by ECG measurement. PR interval had following categories: change from baseline\>=25 percent, 40 to \<60 milliseconds (msec), 60 to \<80 msec and \>=80 msec. Baseline was defined as the average of the triplicate measurements prior to the first dose of study drug.
| Participants | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Substudy |
|---|---|---|---|---|---|---|---|
| Change from baseline: >25% | 4 | 3 | 8 | 9 | 6 | 10 | 2 |
| Absolute value: 40-<60 msec | 3 | 2 | 2 | 2 | 3 | 7 | 2 |
| Absolute value: 60-<80 msec | 0 | 1 | 2 | 4 | 1 | 1 | 0 |
| Absolute value: >=80 msec | 1 | 0 | 0 | 1 | 1 | 2 | 0 |
Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.
| Percentage of participants | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | Phase 2 | DDI Sub-study |
|---|---|---|---|---|---|---|---|
| Objective response | 90.0 (73.5 to 97.9) | 77.8 (57.7 to 91.4) | 56.7 (43.2 to 69.4) | 40.0 (28.0 to 52.9) | 37.0 (23.2 to 52.5) | 38.3 (24.5 to 53.6) | 40.6 (23.7 to 59.4) |
| Intracranial objective response | 75.0 (34.9 to 96.8) | 58.8 (32.9 to 81.6) | 66.7 (48.2 to 82.0) | 53.3 (37.9 to 68.3) | 43.2 (27.1 to 60.5) | 56.0 (34.9 to 75.6) | 25.0 (7.3 to 52.4) |
Collected over From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10 mg QD (Phase 1) | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| 25 mg QD (Phase 1) | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| 50 mg QD (Phase 1) | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| 75 mg QD (Phase 1) | 6/12 (50%) | 6/12 (50%) | 12/12 (100%) |
| 100 mg QD (Phase 1) | 9/17 (52.9%) | 10/17 (58.8%) | 17/17 (100%) |
| 150 mg QD (Phase 1) | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| 200 mg QD (Phase 1) | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| 35 mg BID (Phase 1) | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| 75 mg BID (Phase 1) | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| 100 mg BID (Phase 1) | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Japan Lead-In Cohort (LIC) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| EXP-1 (Phase 2) | 8/30 (26.7%) | 15/30 (50%) | 30/30 (100%) |
| EXP-2 (Phase 2) | 13/27 (48.1%) | 11/27 (40.7%) | 27/27 (100%) |
| EXP-3 (Phase 2) | 25/60 (41.7%) | 34/60 (56.7%) | 59/60 (98.3%) |
| EXP-4 (Phase 2) | 46/65 (70.8%) | 31/65 (47.7%) | 65/65 (100%) |
| EXP-5 (Phase 2) | 37/46 (80.4%) | 23/46 (50%) | 45/46 (97.8%) |
| EXP-6 (Phase 2) | 22/47 (46.8%) | 21/47 (44.7%) | 47/47 (100%) |
| DDI Substudy | 17/32 (53.1%) | 13/32 (40.6%) | 32/32 (100%) |
| Event | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | Japan Lead-In Cohort (LIC) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Substudy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/3 | 0/3 | 0/3 | 0/12 | 2/17 | 2/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 4/30 | 4/27 | 3/60 | 5/65 | 2/46 | 1/47 | 1/32 |
| Cardiac arrestCardiac disorders | 0/3 | 0/3 | 0/3 | 0/12 | 0/17 | 0/3 | 0/3 | 1/3 | 0/3 | 0/4 | 0/3 | 0/30 | 0/27 | 0/60 | 0/65 | 0/46 | 1/47 | 0/32 |
| Pericardial effusionCardiac disorders | 0/3 | 0/3 | 0/3 | 0/12 | 0/17 | 0/3 | 1/3 | 1/3 | 0/3 | 0/4 | 0/3 | 1/30 | 0/27 | 0/60 | 1/65 | 2/46 | 1/47 | 0/32 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/12 | 0/17 | 0/3 | 0/3 | 0/3 | 1/3 | 0/4 | 0/3 | 0/30 | 0/27 | 0/60 | 0/65 | 0/46 | 0/47 | 0/32 |
| Disease progressionGeneral disorders | 1/3 | 1/3 | 0/3 | 1/12 | 4/17 | 1/3 | 0/3 | 0/3 | 1/3 | 0/4 | 0/3 | 2/30 | 0/27 | 7/60 | 8/65 | 6/46 | 6/47 | 5/32 |
| CellulitisInfections and infestations | 0/3 | 0/3 | 0/3 | 0/12 | 0/17 | 0/3 | 1/3 | 0/3 | 0/3 | 0/4 | 0/3 | 2/30 | 1/27 | 0/60 | 0/65 | 0/46 | 0/47 | 0/32 |
| PyelonephritisInfections and infestations | 0/3 | 0/3 | 0/3 | 0/12 | 0/17 | 0/3 | 1/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/30 | 0/27 | 0/60 | 0/65 | 0/46 | 0/47 | 0/32 |
| Respiratory tract infectionInfections and infestations | 0/3 | 0/3 | 0/3 | 0/12 | 0/17 | 0/3 | 1/3 | 0/3 | 0/3 | 0/4 | 0/3 | 2/30 | 1/27 | 0/60 | 0/65 | 0/46 | 1/47 | 0/32 |
| Urinary tract infectionInfections and infestations | 0/3 | 0/3 | 0/3 | 0/12 | 1/17 | 0/3 | 1/3 | 0/3 | 0/3 | 0/4 | 0/3 | 1/30 | 1/27 | 1/60 | 1/65 | 0/46 | 0/47 | 0/32 |
| FallInjury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 0/12 | 0/17 | 0/3 | 1/3 | 0/3 | 0/3 | 0/4 | 0/2 | 1/30 | 0/27 | 0/60 | 5/65 | 0/46 | 0/47 | 1/32 |
| Event | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | Japan Lead-In Cohort (LIC) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | DDI Substudy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 3/12 | 7/17 | 3/3 | 1/3 | 1/3 | 2/3 | 2/4 | 0/3 | 6/30 | 2/27 | 6/60 | 18/65 | 7/46 | 7/47 | 8/32 |
| Oedema peripheralGeneral disorders | 3/3 | 1/3 | 1/3 | 4/12 | 10/17 | 3/3 | 1/3 | 0/3 | 2/3 | 3/4 | 1/3 | 13/30 | 15/27 | 33/60 | 25/65 | 16/46 | 25/47 | 14/32 |
| Alanine aminotransferase increasedInvestigations | 0/3 | 0/3 | 0/3 | 3/12 | 4/17 | 0/3 | 0/3 | 0/3 | 0/3 | 1/4 | 2/3 | 6/30 | 2/27 | 12/60 | 7/65 | 8/46 | 7/7 | 1/32 |
| Blood cholesterol increasedInvestigations | 0/3 | 0/3 | 0/3 | 6/12 | 4/17 | 1/3 | 0/3 | 0/3 | 0/3 | 1/4 | 3/3 | 11/30 | 13/27 | 19/60 | 19/65 | 16/46 | 19/47 | 17/32 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 1/3 | 2/3 | 1/3 | 7/12 | 12/17 | 2/3 | 3/3 | 1/3 | 1/3 | 1/4 | 0/3 | 16/30 | 14/27 | 33/60 | 38/65 | 27/46 | 25/47 | 15/32 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/3 | 1/3 | 1/3 | 5/12 | 7/17 | 1/3 | 2/3 | 0/3 | 1/3 | 1/4 | 3/3 | 23/30 | 16/27 | 37/60 | 45/65 | 32/46 | 25/47 | 23/32 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/3 | 1/3 | 1/3 | 0/12 | 0/17 | 3/3 | 0/3 | 1/3 | 0/3 | 0/4 | 0/3 | 2/30 | 1/27 | 3/60 | 2/65 | 5/46 | 4/47 | 0/32 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/3 | 1/3 | 1/3 | 3/12 | 4/17 | 0/3 | 0/3 | 3/3 | 1/3 | 2/4 | 1/3 | 8/30 | 6/27 | 22/60 | 18/65 | 11/46 | 17/47 | 10/32 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 3/12 | 4/17 | 1/3 | 2/3 | 0/3 | 0/3 | 3/4 | 0/3 | 11/30 | 6/27 | 12/60 | 22/65 | 9/46 | 9/47 | 5/32 |
| NauseaGastrointestinal disorders | 1/3 | 1/3 | 0/3 | 3/12 | 4/17 | 0/3 | 1/3 | 0/3 | 1/3 | 3/4 | 1/3 | 6/30 | 7/27 | 9/60 | 18/65 | 10/46 | 9/47 | 3/32 |
The safety analysis set included all enrolled patients who receive at least one dose of PF-06463922 (including Lead-in dose).
| Age, Customized(Participants) | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | Japan Lead-In Cohort (LIC) | Drug-drug Interaction (DDI) Sub-study | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18-44 years | 0 | 1 | 0 | 5 | 7 | 1 | 1 | 0 | 0 | 2 | 4 | 5 | 14 | 19 | 13 | 12 | 2 | 5 | 91 |
| 45-64 years | 1 | 1 | 3 | 6 | 9 | 1 | 2 | 2 | 2 | 1 | 18 | 13 | 34 | 37 | 26 | 27 | 1 | 20 | 204 |
| >=65 years | 2 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 | 9 | 12 | 9 | 7 | 8 | 0 | 7 | 69 |
| Sex: Female, Male(Participants) | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | Japan Lead-In Cohort (LIC) | Drug-drug Interaction (DDI) Sub-study | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 0 | 1 | 7 | 11 | 2 | 2 | 2 | 3 | 2 | 13 | 17 | 38 | 37 | 25 | 27 | 2 | 15 | 206 |
| Male | 1 | 3 | 2 | 5 | 6 | 1 | 1 | 1 | 0 | 2 | 17 | 10 | 22 | 28 | 21 | 20 | 1 | 17 | 158 |
| Race/Ethnicity, Customized(Participants) | 10 mg QD (Phase 1) | 25 mg QD (Phase 1) | 50 mg QD (Phase 1) | 75 mg QD (Phase 1) | 100 mg QD (Phase 1) | 150 mg QD (Phase 1) | 200 mg QD (Phase 1) | 35 mg BID (Phase 1) | 75 mg BID (Phase 1) | 100 mg BID (Phase 1) | EXP-1 (Phase 2) | EXP-2 (Phase 2) | EXP-3 (Phase 2) | EXP-4 (Phase 2) | EXP-5 (Phase 2) | EXP-6 (Phase 2) | Japan Lead-In Cohort (LIC) | Drug-drug Interaction (DDI) Sub-study | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WHITE | 2 | 2 | 3 | 7 | 13 | 2 | 2 | 1 | 2 | 3 | 10 | 13 | 25 | 32 | 27 | 25 | 0 | 21 | 190 |
| BLACK | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 6 |
| ASIAN | 0 | 1 | 0 | 3 | 2 | 0 | 1 | 0 | 0 | 0 | 17 | 10 | 23 | 23 | 14 | 16 | 3 | 11 | 124 |
| Others | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 3 | 2 | 3 | 0 | 0 | 13 |
| Unspecified | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 10 | 7 | 3 | 2 | 0 | 0 | 31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jan 2014 to primary completion in Mar 2017, 38 months.
Results were first posted in May 2018, 1 year 2 months after primary completion.
Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 38 months is below that.
Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorlatinib
Carcinoma, Non-Small-Cell Lung →